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Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer and 
accounts for 10-15% of breast cancer cases. Due to absence of estrogen, progesterone, and 
human epidermal growth factor receptors, there is lack of targeted therapies and chemotherapy 
remains the mainstay treatment. Moreover, drug resistance is a major problem associated 
specifically with TNBC. Similarly, while estrogen receptor positive (ER+) breast cancer can be 
treated with targeted therapies such as tamoxifen, 40% of patients develop resistance and 
resulting in recurrence of the disease.  
 
There is a dire need for identifying novel targets and developing therapeutics to target 
triple-negative and tamoxifen-resistant (TAMR) breast cancers. Activation of one of the newest 






(ERK) 5 is known to increase cell viability, proliferation, and migration in different cancers and 
its overexpression correlates with poor patient survival. In breast cancer, activation of mitogen 
activated protein kinase kinase (MEK) 5, the upstream kinase of ERK5, and/or ERK5 promotes 
drug resistance, the epithelial to mesenchymal transition (EMT), and hormone independence. 
Once the cancer cells undergo an EMT, they are harder to target and contain, leading to 
metastases. Therefore, there is an urgent need to understand the pathways that drive proliferation 
and the EMT and develop novel therapies that target these pathways.   
 
TNBCs are heterogeneous in their mutational profile and reliance on specific signaling 
pathways. Therefore, in addition to the ERK5 pathway, the ERK1/2 and phosphoinositol-3-
kinase (PI3K)-AKT pathways have been shown to have overlapping and distinct functions as the 
ERK5 pathway to regulate tumorigenesis in TNBC and TAMR breast cancers. Interestingly, 
inhibition of one of these signaling pathways often leads to a compensatory increased activation 
of the other signaling cascades, including the PI3K-AKT pathway. Emerging evidence suggests 
that the MAPK and PI3K pathways play an important role in the progression and metastases of 
other aggressive cancers such as glioblastoma multiforme.  
 
The main goals of this project are 1) to target the ERK1/2 and ERK5 pathways and 
develop strategies to reverse the EMT using novel and known pharmacological inhibitors and 
molecular tools and 2) determine the effect of novel and known kinase inhibitors on 
chemotherapeutic sensitivity and 3) determine the effect of novel compounds that target the 
ERK1/2 and ERK5 pathways in combination with the AKT inhibitor ipatasertib on spheroid 
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Chapter 1: Literature Review 
1.1 Introduction 
1.1 .1 Breast Cancer  
Cancer is the second leading cause of death in the United States with 1.8 million 
new cancer cases and 0.6 million deaths estimated for 2020.1 Among these cases are 0.28 million 
new breast cancer cases with 42,000 anticipated deaths anticipated for the year 2020.  
Metastases accounts for 90% of deaths due to cancer. Cancers display  phenotypes2-3  
of increased self-sufficiency in growth signaling, an insensitivity to anti-growth signals, 
increased tissue invasion and metastasis, limitless replication potential, sustained 
angiogenesis, and evasion of apoptotic cell death. Breast cancer accounts for 30% of all 
cancers occurring in women and triple-negative breast cancer (TNBC), which constitutes 








Figure 1.1: Metastatic breast cancer. Metastatic breast cancer is challenging to treat 
due to its aggressive nature and lack of well-defined therapeutic targets (Image source: 
https://www.cancersupportcommunity.org/metastatic-breast-cancer). Courtesy of Bob 
Morreale. 
The normal mammary lobule consists of aggregate of acini embedded in the 
surrounding stroma. The acini drain into a terminal ductule and a few lobules and ductules 
drain together to form terminal duct lobular unit. The inner lining of the ducts and lobules 
comprises of an inner epithelial layer, which stains positive for the transmembrane 
adhesion molecule E-cadherin encoded by the CDH1 gene. Growth and differentiation of 
normal breast tissue is regulated by estrogen and progesterone via estrogen and 
progesterone receptors, respectively.  
Breast carcinomas are comprised of transformed epithelial cells. Breast cancers 
progress from regions of cellular atypia into clinically evident premalignant or malignant 






cancer is very heterogeneous in terms of histology, response to therapy, metastatic 
patterns, and patient outcomes. Breast cancers can be classified based on the different 
molecular subtypes, stage of disease, and grade (Figure 1.2). Global gene expression 
analyses and high-throughput sequencing have helped characterize breast cancer as 
Luminal A, Luminal B, HER2-enriched, claudin-low, and basal-like. 
  
Figure 1.2: Histologic and molecular subtypes of breast cancer. Breast cancer can 
be classified based on the origin, stage, and molecular subtypes (Image source: 









1.1.2 Triple-negative breast cancer 
TNBCs lack HER2, ER, and PR receptor expression, yet retain the growth normally 
expected from activation of these receptors.  It has been proposed that the pathways 
display increased activity decoupled from receptor occupancy.  Most TNBCs and drug-
resistant cancers adapt to develop a mesenchymal phenotype over time. Epithelial to 
mesenchymal transition is the first step of metastases, which accounts for ~90% of 
cancer-associated deaths in humans. EMT is a cascade of cellular events including the 
loss of epithelial marker E-cadherin and gain of mesenchymal markers ZEB1, snail, and 
vimentin. Loss of E-cadherin expression is a crucial event in the metastases and 
recurrence of aggressive lobular breast cancer.5-6  
 
1.1.3 Epithelial to mesenchymal transition and cancer metastases 
The epithelial to mesenchymal transition (EMT), one of the first steps in cancer 
metastases, is a continuum of morphologic transitions from cobblestone-like epithelial 
state to a spindle-like mesenchymal state (Figure 1.3). The complex process of 
metastases involves EMT, intravasation in the blood vessels, survival in blood stream, 
extravasation at the secondary site, mesenchymal to epithelial transition (MET), and 
secondary tumor growth.7 Cells can also exist in an epithelial/mesenchymal stage, where 
they co-express epithelial and mesenchymal markers. This intermediate EMT state is 
often associated with greater metastatic potential and poor patient outcome. Cancer 
metastases requires high cellular plasticity and adaptability to survive in diverse 






of metastases. Upregulation of EMT transcription factors via growth factors, epigenetic 
plasticity, and downregulation of tumor suppressor microRNAs (miRs) are a few 
mechanisms that drive EMT in cancer.8  
 
Figure 1.3: Events involved in epithelial to mesenchymal transition.9  
 
Tumor heterogeneity in terms of difference in driver mutations within the same 
cancer subtype and complexity of the tumor microenvironment have made the application 
of oncology therapeutics extremely challenging. The extracellular signaling factors and 
epigenetic effectors cooperate to initiate the EMT program and ultimately lead to 
metastases. One of the cellular adaptations during EMT involves increased capabilities 
of cancer cells to preferentially interact with the extracellular matrix, rather than the 






adhesion kinases (FAK), which results in an increase in secretion of matrix 
metalloproteinases, loss of E-cadherin, and disruption of the adherens junctions (AJs).10  
Tumor-associated chronic inflammation could initiate EMT via crosstalk between 
the inflammatory and tumor cells.11 The tumor is infiltrated by diverse inflammatory and 
immune mediators. For example, 50% of the tumor is infiltrated with inflammatory 
macrophages. These infiltrated activated macrophages and proinflammatory T-cells can 
release cytokines, including transforming growth factor-β (TGF- β), tumor necrosis factor 
α (TNF- α), and interleukin-6, which are potent EMT inducers.12 Expression of immune 
checkpoint proteins such as PD-L1 mediates escape of cancer cells from NK cell-
mediated cytotoxicity. In the given feedforward mechanism, EMT increases in PD-L1 
expression via the microRNA-200-ZEB1 axis, which results in immune suppression and 
metastases.13 Several mechanisms that regulate EMT are summarized in Figure 1.4. 
 
Figure 1.4: Mechanisms that drive EMT in cancer. EMT in gradual progression from a 
cobblestone-like morphology to spindle-like morphology, initiated by growth factors, 
activation of MAPK pathway, and upregulation of transcription factors involved in EMT. 






Another feature that the cancer cells adopt as they transition to a mesenchymal 
state and enter the blood circulation for metastases is their ability to activate and bind 
platelets. At this stage, the cancer cells are termed as circulating tumor cells. Many 
studies argue that the cells are in an intermediate epithelio-mesenchymal state at this 
stage. There are coagulation-dependent mechanisms modulated via fibrin, which help the 
cancer cells to bind platelets and gain protection against loss of anchorage-triggering 
anoikis, immune attack, and shear stress.14 Drug resistant stem cells at the primary and 
metastatic sites are also known to possess EMT characteristics.15 
1.1.4 The Mitogen-Activated Protein Kinase Pathway in cancer 
MAPK pathway is activated in response to growth factors, cytokines, stress, and 
hormones and leads to alteration of cell division, proliferation, and differentiation. 
Mutations in BRAF, KRAS, EGFR, and receptor tyrosine kinase (RTK) pathways can lead 
to constitutive activation of MAPK pathway, characterized by phosphorylation of 
downstream targets MAPK/ERK Kinase Kinase 2 (MEKK2)/3, ERK1/2, ERK5, RSK, and 
FRA-1. Figure 1.5 summarizes the intracellular signaling pathways, which are involved in 







Figure 1.5: Pathways driving ERK activation and cellular process regulated by the 
kinase.16 
 
Activation of MAPK can increase EMT, migration, invasion, and stemness in 
several cancers. Extracellular-regulated kinase (ERK)1/2 is one of the most well-
characterized members of the MAPK pathway. ERK1/2 activation can be a result of 
tyrosine kinase dimerization, RAS, or RAF mutation. RTKs serve as binding sites for the 
Src homology and collagen (SHC) adapter protein and growth factor receptor-bound 






domains. GRB2 then interacts with Son of Sevenless (SOS) through its SH3 domain, 
leading to the activation of MEK1/2 and MEK5.  
1.1.4.1 ERK1/2 pathway in cancer 
Extracellular signal-regulated kinase (ERK)1 and ERK2 isoforms share 85% 
sequence homology and can be activated by phosphorylation at the TEY motif (Thr202 
and Tyr204).17 The ERK1/2 pathway is one of the most well characterized MAPK 
pathways in cancer (Figure 1.6). The MAPK cascade and subsequent ERK1/2 is initiated 
when an extracellular signal activates the corresponding receptor and causes 
conformational changes and activation of the small GTPase RAS at the plasma 
membrane. RAS activates Raf-MEK-ERK by phosphorylation of serine residues. This 
pathway is activated in 85% of all cancers due to mutations in RAS, RAF, MEK or 
epidermal growth factor receptor (EGFR). ERK1/2 activation leads to subsequent 
activation of downstream effectors and gene transcription. These signals are amplified at 
each stage. ERK1/2 is known to induce fos and jun, Activator protein 1 (AP-1), 
Erythroblast Transformation Specific ETS-1 genes. Moreover, ETS-1 has been found to 
upregulate ZEB1 expression and regulate EMT in breast cancer.18  
Connexin 43 (inhibitor of gap junction communication) and regulator of cell 
migration myosin light chain kinase (MCLK) are plasma membrane proteins activated by 
ERK1/2.19 ERK1/2 activation leads to association of paxillin to Src.20 Ribosomal S6 kinase 
(RSK), mitogen and stress-activated protein kinase (MSK), and MAPK-interacting kinase 
(MNK) are the main cytoplasmic substrates of ERK.21 RSK family are known to be 
exclusively activated by ERK1/2 but we have found that ERK5 can also modulate RSK 






serum response factor (SRF), estrogen receptor (ER) is modulated by RSK activation. 
RSK also regulates pro-apoptotic protein Bcl-2-associated death promoter (BAD). Direct 
and indirect regulators of ERK1/2 signaling cascade and downstream effectors are 
summarized in figure 1.5. While ERK1/2 pathway in cancer is well-understood, the details 
about ERK5 pathway in cancer are only being recently explored.    
RAS is an important regulator of ERK1/2 pathway. RAS mutation can promote 
cancer growth via influencing several hallmarks of cancer described by Weinberg et. al.: 
Sustained growth and proliferation, evasion of immune system, invasion, inhibition of 
apoptotic signaling, EMT, and alteration of cell metabolism. Reasons why RAS is 
undruggable include: (i) binding of RAS to GTP (covalent interaction) results in the closing 
of GTP-binding domain on RAS, thus making the binding pocket inaccessible for RAS 
inhibitors. (ii) Unique C-terminal domain: C-terminal domain of RAS can undergo post-
translational modifications, including palmitoylation and farnesylation. Several 
approaches were developed to target these post-translational modifications. However, 
RAS mutant cancer cells adapted to develop an alternative PTM mechanism known as 
GGTase (geranylgeranyl isoprenoid), preventing RAS from turning off. Therefore, 
targeting the downstream effector of RAS signaling including the MEK1/2-ERK1/2 and 








Figure 1.6: Upstream and downstream regulators of the ERK1/2 pathway22 
1.1.4.2 ERK5 pathway in cancer   
ERK5, the newest member of the mitogen-activated protein kinase family (MAPK), 
is a marker for poor prognosis in cancer patients.23 ERK5 is one of the members of the 4 
MAPK signaling cascades, including ERK1 and ERK2, c-JUN N-terminal kinase (JNK) 1, 
and p38-MAPK. These cascades are regulated by 3 to 5 tiers of phosphorylation events, 
which are initiated by receptor tyrosine kinases and subsequent components of the MAPK 
family. While these pathways are under strict regulation by feedforward activation and 






Although ERK1/2 and ERK5 pathways share greater than 50% sequence 
homology at the N-terminal domain, ERK1/2 and ERK5 have been shown to mediate 
differential responses to growth factors, hypoxia, and pharmacological targeting with 
BRAF and MEK1/2 inhibitors. ERK1/2 and ERK5 pathways regulate hypoxia-related 
genes via distinct mechanisms in normoxic versus hypoxic condition.24  These differences 
could be attributed to the unique C-terminal domain of ERK5, which contains two proline-
rich regions and a nuclear localization sequence and facilitates transcriptional activation 
of oncogenes.25 We have most recently studied the overlapping and distinct functions of 
ERK1/2 and ERK5 signaling in regulating EMT in triple negative and tamoxifen-resistant 
breast cancer.26 
High ERK5 expression correlated with EMT, drug resistance, and poor patient 
survival in several cancers.27-30 Whole-genome microarray analysis revealed that 
overexpression of cyclin-dependent kinase 5 (CDK5), an important prognostic marker for 
development of malignant CRC in human samples, could directly activate ERK5 and 
promote progression of colorectal cancer via AP-1.31 ERK5 negatively correlated with 
miR-143 expression and regulated proliferation, migration, and invasion in 
osteosarcoma.32-33 DNA damage initiates apoptotic signaling cascade via activation of 
ataxia-telangiectasia mutated (ATM) kinase, which is a cell cycle regulator and mediates 
phosphorylation of DNA damage and repair marker H2AX. Loss-of-function mutation in 
ATM is one of the causes of cancer and ERK5 deletion in ATM-/- mice has been shown 
to delay tumorigenesis and increase response to DNA-targeting agents via H2AX 
phosphorylation in thymic lymphoma.34 This was one of the few studies to identify the role 






1.1.4.3 Mechanisms for dysregulated ERK5 signaling in cancer 
Activating mutations in genes such as BRAF (70% melanoma, 59% thyroid, 10% 
colon, and 6.7% lung cancer)35 and KRAS (90% pancreatic, 50% thyroid, 30% lung, 15% 
ovarian, breast, liver, kidney cancer, and leukemias) have a major influence on MAPK 
signaling in several cancers. Most of these cancers have FDA-approved therapies as a 
line of treatment, but it becomes really challenging to treat these cancers once they 
metastasize. BRAF mutations in particular are known to mediate the EMT and 
metastases via hyperactivation of the MAPK, nuclear factor kappa B (NF-kB), and 
phosphatidyl inositol-3-kinase (PI3K)/AKT pathways.36  
ERK5 and AKT pathways are known to transactivate each other and regulate cell 
survival via phosphorylation and cytosolic sequestration of the pro-apoptotic protein Bad 
in triple negative breast cancer (TNBC).37 Moreover, PI3K/AKT pathway is also known to 
mediate MEK5-ERK5 activation in malignant mesothelioma and neuroblastoma.38-39 
Hepatocyte growth factor (HGF) and its receptor c-met are also known to activate ERK5 
and upregulate one of the downstream targets fos-related antigen-1 (FRA-1) via PI3K-
AKT signaling in malignant mesotheliomas (MMs).38 HGF also induced ERK5 and protein 
tyrosine kinase (PTK) 6 activation and cell migration in breast cancer cells.40 Platelet-
derived growth factor (PDGF) BB increased bone morphogenetic protein (BMP) signaling 
in fibroblasts via PI3K-MEK1/2-MEK5-ERK5 activation.41 Interleukin-6 is known to 
promote ERK5 activation and proliferation in multiple myeloma.42 
Hyperactivation of ERK5 could be a result of downregulation of tumor suppressor 
proteins, microRNAs, or phosphatases/ proteases that inhibit ERK5 via a negative 






RNAs and their function is to silence protein expression post-transcriptionally. These bind 
with the 3’-untranslated region (UTR) of the target mRNAs, leading to their translational 
repression or destabilization. Loss of tumor suppressor miRs is an important mechanism 
responsible for the overexpression of oncoproteins. Some studies suggest that ERK5 is 
negatively regulated by tumor suppressor miRNAs miR-143 and miR-200 in breast cancer 
and glioblastoma, respectively.43-44  
Downregulation of transcription factor special AT-rich sequence-binding protein 2 
(SATB2) via miR-31, miR-34, or TGF-b signaling has been indicated to be associated 
with cancer progression.45 High SATB2 expression correlates with favorable prognosis 
and enhanced chemosensitivity in colorectal cancer (CRC).45-46 Overexpression of 
SATB2 increased the epithelial marker E-cadherin, decreased mesenchymal markers 
vimentin, N-cadherin in CRC cell lines in vitro, and suppressed metastases in vivo.47 
SATB2 was identified to inhibit ERK5 activity and decrease CRC cell migration, invasion, 
and colony formation in vitro and tumor progression in vivo.48 However, the total ERK5 
expression was unaffected, indicating that SATB2 may not transcriptionally regulate 
ERK5. Finally, ERK5 degradation is mediated by the tumor suppressor von Hippel-Lindau 
(VHL) through prolyl hydroxylation-dependent ubiquitination and subsequent 
proteasomal degradation.49 VHL gene is often mutated in clear cell renal cell carcinoma 
(CCRCC). Hypoxia-inducible factor-1α (HIF-1α), one of the major targets of VHL-
mediated degradation, mediates the survival of cancer cells under low oxygen 
conditions.50 Disease-specific survival was greater with high ERK5 and HIF-1α 
expression and low VHL expression in CCRCC patients, indicating ERK5 as an essential 







Figure 1.7: Upstream and downstream regulators of EMT mediated via ERK5. 
Original figure created in Biorender.com. 
 
1.1.4.4 Crosstalk between the ERK1/2 and ERK5 pathways 
Crosstalk among the different members of the MAPK family, including ERK1/2 and 
ERK5, has been noted. ERK1/2 and ERK5 are known to commonly regulate downstream 
targets such as RSK, c-Fos, and CD-1. We have shown that novel inhibitors of MEK1/2 
and MEK5 pathways reverse the mesenchymal phenotype of MDA-MB-231 TNBC cells 
to epithelial and increase E-cadherin protein expression.51 Some studies revealed that 
targeting the ERK1/2 pathway can lead to a compensatory increase in ERK5 activation 
via upregulation of c-MYC or IGFR.52-55 ERK5 can compensate for targeting ERK1/2 to 






mediated macrophage differentiation in acute myeloid leukemia cells.56 Inhibition of both 
ERK1/2 and ERK5 has been found to be necessary for efficient targeting of NRAS and 
BRAF-mutant melanomas.52, 54-55, 57 On the contrary, ERK5 has been found to be 
downstream of the BRAF-MEK1/2-ERK1/2 signaling in melanoma and ERK1/2 is known 
to promote nuclear localization of ERK5 in HEK293 and PC12 cells via Thr732 
phosphorylation (Figure 1.8).58-59 Although the MEK1/2-ERK1/2 pathway is fairly 
understood in regulating EMT in cancer, the involvement of the MEK5-ERK5 pathway in 
EMT is overlooked (293 versus 22 results in Pubmed search). ERK1/2 and ERK5 were 
thought to have redundant roles, our research goals include examining distinct and 
overlapping roles of ERK1/2 and ERK5 pathways on MET in breast cancer. Roles of 
ERK1/2 and ERK5 pathways in regulating EMT are discussed in more detail in chapter 
four.  
 






1.1.5 PI3K/AKT pathway in cancer 
The crosstalk between MAPK and PI3K pathways has been noted in cancer.61 In 
our study, we propose dual inhibitors of MEK5 and PI3K pathways as a strategy to target 
cancer. Therefore, this section includes the details on the PI3K/AKT signaling pathway. 
The PI3K/AKT signaling pathway is involved in proliferation, cell survival, apoptosis, 
differentiation, vacuolar trafficking, and cytoskeletal rearrangement. Class I PI3K family 
of proteins are implicated in cancer, which is activated by receptor tyrosine kinase, G-
protein coupled receptor, and various oncoproteins. The 110-kDa catalytic subunit (p110) 
of PI3K is associated with an 85-kDa adapter, non-catalytic subunit (p85). p85 subunit is 
encoded by various genes that code for multiple proteins with distinct function, most of 
the splice variants, and adapter subunits two Src-homology 2 (SH2) domains. A p110-
binding domain is located between the two SH2 domains, which allows for the interaction 
and stabilization of p110 protein and inhibition of the PI3K kinase activity.62  
Phosphorylation of tyrosine at the growth factor receptor recruits p85 to the cell 
membrane, relieving its inhibition on p110. Subsequently, PI3K colocalizes with its 
regulatory molecules and substrate membrane phosphatidylinositols.63 The PI3K-AKT 
pathway is illustrated in figure 1.9. 
PI3K complex is recruited from the cytoplasm to the inner cell membrane when 
growth factor binds to the receptor tyrosine kinases. PI3K phosphorylates and converts 
its substrate phosphatidylinositol (4,5) bisphosphate (PIP2) at the 3-position of the inositol 
ring to form the secondary messenger phosphatidylinositol (3,4,5) triphosphate (PIP3). 






(PTEN). The levels of PIP3 are controlled by SH2-containing inositol-5-phosphatase 
(SHIP).64 PIP3 is an anchor for proteins such as AKT1, AKT2 and AKT3, which contain 
Pleckstrin Homology (PH) domain. These proteins are activated by 3-phosphoinositide 
dependent protein kinase-1 (PDK1) when localized to the membrane; further activation 
of downstream targets such as mTOR, Bad, Caspase 9, GSK3B, tuberin, and certain 
forkhead transcription factors is initiated.65-67 
The major targets of the PI3K/AKT pathway include PI3Ks, PDK1, AKT, and 
mTOR. The most common research tools used to inhibit this pathway include LY294002 
and wortmannin, which target the catalytic site of p110. LY294002 did not pass clinical 
trials because of its unfavorable pharmacokinetic profile and toxicity. New inhibitors of the 
class imidazopyridines, quinazolyne, pyridopyrimidines, thiazoles that target the catalytic 
ATP-binding pocket are in development.68  
1.1.5.1 p110: the catalytic subunit: 
The catalytic class I PI3K isoforms of p110: p110α, p110β, p110δ, and p110γ are 
known to preferentially govern cell signaling and tumor cell survival depending upon the 
malignancy and the genetic or epigenetic aberrations.69 Simultaneous mutations are 
frequent in triple-negative breast cancer, endometrial, and prostate cancer. However, 
many cancers respond much better to single isoform inhibition when compared to pan-
PI3K inhibition. The two distinct functions of p110 isoforms p110a and p110b have been 
recently studied, which provide a platform for targeting the pathway in the context of the 
oncogenic driver of AKT signaling: PIK3CA mutation or PTEN loss. Hence, isoform 






PIK3CA mutation driven cancers are dependent on p110a signaling, however, 
p110b is the major isoform known to drive tumorigenesis in PTEN deficient cancers. 
PIK3CA mutant cell lines exhibit greater sensitivity to pan-PI3K inhibitors compared to 
PTEN deficient cancers. Similar response has been observed in the clinic.70 This might 
be the case because pan-PI3K inhibitors are more potent against p110a isoform versus 
the p110b isoform. 
The importance of developing isoform specific inhibitors is to target specific 
mutations in the PI3K pathway and avoid cumulative toxicity of inhibiting irrelevant 
targets. Most cancers characterized by PI3KCA mutation or amplification are more 
sensitive to p110a inhibitors such as INK1402, which led to 80-100% growth inhibition 








Figure 1.9: The PI3K-AKT pathway in human cancer.71  
1.1.5.2 Targeting specific p110 isoforms: 
The development of isoform specific inhibitors helped to delineate the functional 
role of p110α and p110β. The p110α knockout mice were embryonic lethal at day 9.5-
10.5, and the embryos showed proliferative defects and impaired insulin signaling.72 The 






growth and insulin signaling with homozygous and heterozygous kinase-dead p110a 
knock-in, respectively, indicating a kinase dependent function of the p110a isoform.73 
p110β knockout also leads to early embryonic lethality and impaired cell proliferation. 
However, p110b-null MEFs reconstituted with a p110b kinase-dead allele survive 
normally, suggesting a kinase independent function of the p110b isoform, and its role as 
an important scaffold.74-75 
A panel of breast cancer cells MCF7, BT474, BT20, and BT47D with mutant p110a 
are sensitive to p110a isoform-specific inhibitors.76 Targeting p110a isoform inhibits tumor 
cell proliferation, chemoresistance, and mig77ration in medulloblastoma cells that over-
express p110a. p110a inhibition is effective also in tumors that harbor mutant Ras and 
PTEN deficiency, which exacerbate the oncogenic transformation. Although the rates of 
activating mutations in PIK3CA gene are high, loss of PTEN is the most common 
mechanism for oncogenic PI3K signaling in most cancers. It was misconstrued in the past 
that frequent activation of p110a was the major oncogenic driver and the loss negative 
PI3K regulation by PTEN mutation contributed to the aberrant signaling. However, p110a 
ablation in PTEN mutant cancers did not significantly affect tumorigenesis.78 
 In contrast, p110b targeting sufficiently inhibits downstream AKT activation and 
tumor formation in PTEN deficient prostate cancer.78 It is important to consider that PTEN 
loss could be an amplifier of PI3K signaling coupled to an initial weak signal driven by 
either PIK3CA, GPCR or p110a mutation, which has an influence on the type of response 
to specific isoform inhibition. Cell lines with PTEN loss and coexisting PIK3CA or Ras 






inhibition.79 However, if the signals are initiated from a GPCR, then p110b inhibition would 
be a more relevant strategy to reduce tumor formation. 
1.2 Statement of the Problem  
Reversing epithelial to mesenchymal transition (EMT) is an emerging strategy to 
target the invasive cancers that show poor sensitivity to chemotherapeutic agents. EMT 
is characterized by loss of cell polarity, disruption of intercellular junctions, reorganization 
of the cytoskeleton, downregulation of E-cadherin, and increased cell migration and 
invasion80 Disruption of actin skeleton via ras and src mediated activation of extracellular 
regulated kinase 1/2 (ERK1/2) and ERK5 is reported, indicating their role in oncogenic 
transformation81. Most invasive cancers, including triple negative (TNBC) and tamoxifen 
resistant (TAMR) breast cancers have a mesenchymal phenotype. There are no current 
studies that have explored the role of MAPK inhibitors as inducers of mesenchymal to 
epithelial transition (MET), the reverse process of EMT, in breast cancer. 
Activation of mitogen activated protein kinase (MAPK) pathways, including ERK1/2 
and ERK5 signaling cascades can activate downstream targets such as Fos-related 
antigen (Fra-1), zinc finger E-box binding protein ZEB1, and Slug, which lead to EMT82. 
Several MEK5 independent mechanisms for ERK5 activation and nuclear localization, 
mediated via phosphoinositol-3-kinase (PI3K)/AKT and MEK1/2 pathways, respectively 
have been reported39, 60. A crosstalk between AKT and ERK5 pathways has been 
suggested as a mode of chemoresistance in breast cancer cells. The goal of this research 






EMT, crosstalk with the AKT pathway, and chemoresistance in mesenchymal breast 
cancer cells.  
1.2.1 Research Objectives 
1.2.2 Hypothesis and Specific Aims: 
Hypothesis: MEK5 and MEK1/2 or PI3K pathway inhibition will reverse epithelial to 
mesenchymal transition and enhance chemotherapeutic drug sensitivity in breast and 
brain cancers.  
Specific Aim 1: To elucidate the structure-activity relationship of novel diphenylamine 
analogs that induce mesenchymal to epithelial transition in breast cancer. 
Specific Aim 2: To elucidate the effect of targeting the ERK1/2 and ERK5 pathways 
using pharmacological inhibitors and molecular tools on MET in breast cancer.   
Specific Aim 3: To examine the effect of ERK1/2, AKT, and ERK5 pathway inhibitors on 
chemosensitivity in triple negative and tamoxifen resistant breast cancer cells.  
Specific Aim 4: To examine the effect of dual ERK5 and ERK1/2 or AKT inhibition on 










Chapter 2: Methods 
2.1 Cell Culture and Reagents 
MDA-MB-231, MDA-MB-231 VIM RFP, BT-549, MCF-7, and U87MG cell lines 
were obtained from American Type Culture Collection (ATCC). MDA-MB-231 cells were 
maintained in Dulbecco’s Modified Eagle Medium and Ham F-12 (1:1), BT-549 and MCF-
7 cells were maintained in RPMI- 1640 medium, and U87MG cells were cultured in MEM 
medium supplemented with 5% FBS (Gibco) and 0.5% Pen Strep (Gibco) in a humified 
atmosphere containing 5% CO2 at 37◦C. To generate a tamoxifen resistant cell line, MCF-
7 cells were cultured in phenol red-free RPMI-1640 media, supplemented with 5% 
charcoal-stripped FBS in the presence of DMSO or 0.1μM (Z)-4-Hydroxytamoxifen (4-
OHT) (Sigma-Aldrich Cat. No. H7904) for 6 months. Charcoal-stripped FBS was used to 
remove endogenously expressed protein growth factors present in the media (TAMR 
MCF-7 cell line was generated by Dr. Thomas Wright). 
2.2 Inhibitor treatment and EGF stimulation 
To examine the specificity of the kinase inhibitors, cells (500,000 cells/well) were 
cultured in a 6-well plate for 24 hours.  To examine kinase activity or inhibition, the cells 
were serum-starved for 18-24 hours. The inhibitors XMD8-92 (Tocris, Minneapolis, MN), 
Trametinib (Selleckchem, Houston, TX), and VX-11e (Cayman chemical, Ann Arbor, MI) 
were added for 30 minutes prior to EGF (100ng/ml) stimulation for 15 minutes as 
described previously.83 Cell lysates were examined for kinase activation using standard 






2.3 Lentivirus treatment 
Since pharmacological inhibitors may have off-target effects, molecular tools were 
utilized in our study to examine the kinase pathway and EMT/ MET. Lentivirus vectors 
were a generous gift from Dr. Zhengui Xia (University of Seattle, Washington). MDA-MB-
231, MDA-MB-231 VIM RFP, and BT-549 cells were cultured in a 12-well plate (150,000 
cells/ well). The volume of lentivirus (µL) required per well was calculated as [(# of 
cells/well x desired multiplicity of infection (MOI)/viral titer (IU/µL)]. This volume of 
lentivirus was diluted in fresh media. 50% of media was replaced with the lentivirus-
containing media. The transfection efficiency was about 50% after 24 hours of infection 
at MOI=1, as calculated by microscopic observation of the percentage of GFP-positive 
cells. The cells were infected with lentivirus at the MOI =1 for 96 hours. Western blotting 
was performed to examine cell E-cadherin and ZEB1 protein expression or ERK1/2 and 
ERK5 activation, respectively and immunocytochemistry was performed to examine cell 
morphology. 
Lentivirus Vector Titer (IU/ml) Cryobaby color 
GFP 3.35x108 Green 
caMEK5 4x107 Yellow 
dnMEK5 5x106 Yellow 






dnERK5 3.2x107 Yellow 
caMKK1 1.85x107 Orange 
dnMKK1 3.10x107 Blue 
Table 2.1 Lentivirus titer 
2.4 Nuclear/Cytosolic fractionation 
Cells were cultured in 6-well plates (500,000 cells/well) for 24 hours. After 24 
hours, cells were treated with the kinase inhibitors for 72 hours. The nuclear/ cytosolic 
fractionation was performed using standard manufacturer’s instructions (Cell Biolabs, 
San Diego, CA). In brief, the medium was aspirated, and cells were washed with pre-
chilled 1X PBS. DTT and Protease inhibitor cocktail was added to Cytosol Extraction 
Buffer (CEB). 100 µL CEB was added to cells for 10 minutes. Cells were scraped and 
collected in 1.5 mL pre-chilled microcentrifuge tubes. Cell lysis buffer was added for 5-15 
minutes and the lysates were vortexed for 10 seconds. The lysates were centrifuged at 
10,000 rpm for 10 minutes at 4°C. The supernatant (cytosolic fraction) was collected and 
stored at -80°C. The pellet was resuspended in CEB and lysis buffer was added for 10 
minutes. The suspension was vortexed and centrifuged at 10,000 rpm for 10 minutes at 
4°C. The supernatant was discarded, this step was performed to ensure clean separation. 
The pellet was resuspended in 40 µL nuclear extraction buffer (NEB) with DTT and 
protease inhibitors. The solution was incubated on ice for 30 minutes with occasional 
vortexing. The samples were centrifuged at 14,000 rpm for 30 minutes at 4°C. The 






2.5 Western Blot Analysis 
Cells were lysed at experimental endpoint in 1X cell lysis buffer (Cell Signaling 
Technology) and 0.1M PMSF. The proteins were resolved using 8% SDS polyacrylamide 
gel electrophoresis and transferred to nitrocellulose membranes (LI-COR Biosciences; 
Lincoln, NE). The membranes were blocked for 1 h at room temperature and incubated 
at 4°C overnight with respective primary antibodies (Appendix B) diluted in casein 
blocking buffer (LI-COR Biosciences). The membranes were washed three times with 
wash buffer (PBS 1X, Tween 0.02%) at 10-minute intervals. The membranes were 
incubated with goat anti-mouse (1:10000, Invitrogen) and goat anti-rabbit (1:10000, 
Invitrogen) secondary antibodies for 1 h. Membranes were washed three times at 10-
minute intervals with PBS-tween wash buffer and scanned on an LI-COR’s Odyssey CLx 
Imager at 700 nm (goat anti-rabbit) and 800 nm (goat anti-mouse). The blots were 
quantified with LI-COR Image Studio Software.  
2.6 Crystal Violet Staining 
Crystal violet staining was performed to examine cell morphology. Cells (50,000 
cells/well) were seeded in a 12-well plate for 24 hours and treated with 1μM concentration 
of compounds for 5 days. After 5 days, media was aspirated, and cells were gently 
washed with 1X PBS. Cells were fixed with 50 μl 4% paraformaldehyde per well for 15 
minutes. Cells were washed once with 1X PBS and stained with 50 μl crystal violet per 
well for 15 minutes. Cells were washed with 100 μl PBS three times and imaged using 






2.7 Spindle Index Calculation 
Spindle index calculation was performed to quantify cell shape and validate the 
structure-activity relationship of the novel diphenylamines. Spindle indices (SI) of 
individual cells were calculated from at least 200 cells per treatment from at least three 
images as the ratio of length (l) to width (w); SI = l/w of each cell. Cells with SI < 3 were 
considered as epithelial.84 % cells with SI<3 were calculated as the ratio of the number of 
cells with spindle index < 3 to the total number of cells per image. The method was 
adopted from reference 82. Length and width of cells were measured using the Image J 
software, U. S. National Institutes of Health, Bethesda, Maryland, USA. 
 







Figure 2.2: Validating spindle index calculation using panel of breast cancer cell 
lines: Cells with mesenchymal phenotype correspond have SI value > 3. 
2.8 Colony Formation Assay 
Colony formation assay was performed to examine the growth of cells in 3-D 
extracellular matrix-based conditions. Colony formation assay was performed using a Soft 
Agar Colony Formation assay (Cell Biolabs; CBA-130). Briefly, base agar layer was 
added first. MDA-MB-231 cells (5,000 cells/well) were cultured in 5% FBS growth media 
and 1.2% agar solution in a 96-well plate. DMSO or compound 1 (0.1, 1, and 10 μM) 
diluted in media was added on the top of cell layer. The colonies were allowed to grow 
for 7 days. The agar layer was solubilized, the colonies were lysed and stained with 







2.9 Spheroid Culture 
Spheroid culture was performed to examine the effect on cells that have gained 
the ability to survive in anchorage-independent conditions. Cells (5,000 cells/ well) were 
cultured in 96-well low attachment plates (Corning Cat. No. 4520). DMSO or inhibitors 
were added after 24 h of plating. Pictures were taken using the EVOSTM FL inverted 
microscope (Life Technologies) under 4X magnification at the time of treatment and after 
7 days from treatment. 10 μl of Reliablue viability reagent (ATCCR 30-1014TM) was 
added to each well after 7 days from treatment. The plates were incubated in the incubator 
at 37◦C for 3 h. The fluorescence was measured at ex570/ em590 on a Synergy 
microplate reader (Biotek, Winooski, VT). Data is represented as spheroid viability 
normalized to DMSO control ±SEM of triplicate experiments.  
2.10 Immunofluorescence Assay 
Immunofluorescence assay was performed to examine number of proliferating 
cells, cell morphology, and EMT marker ZEB1 after treatment with kinase inhibitors. Cells 
were plated at a density of 5,000 cells/well in a 96-well plate for 24 hours. After 72 hours 
of treatment, cells were fixed with 4% paraformaldehyde for 15min and washed with 1X 
PBS. Cells were blocked for 1 h with 0.3% Triton-X solution in Casein blocking buffer and 
1X PBS. The Primary antibodies α-actinin, α-tubulin, and Ki67 (Cell Signaling 
Technology) were added at a dilution of 1:750 and plate was incubated overnight at 4°C. 
The cells were subsequently washed three times at 5-minute intervals, incubated for 1 h 
with goat anti-mouse Alexa Flour 488 nm and goat anti-Rabbit Alexa Flour 555 nm 






The cells were washed with 1X PBS three times at 5-minute intervals. The plate was 
imaged with the EVOSTM FL inverted microscope (Life Technologies). The proliferative 
index was calculated as the ratio of number of Ki67+ cells to the number of Hoechst+ cells. 
2.11 Scratch Assay 
Cell migration was assessed using a scratch assay after treatment with DMSO or 
inhibitors for 72 hours. Cells were seeded at a seeding density of 50,000 cells/ well in a 
12-well plate in 1ml full media in the presence of 5% FBS. Scratches were made after 48 
h of the treatment (0 hr). The underside of the plate was marked to denote the location of 
the initial wound. Cells were washed gently with 1x PBS to remove detached cells and 
debris. Images were taken at the time of scratch and after 24 h from the time of scratch. 
Cell migration was calculated as wound closure = (border width at 24 h-border width at 0 
h)/ (border width at 0 h) X 100. Results are represented as cell migration normalized to 
DMSO control ± SEM of experiments repeated three times. The principle behind cell 
migration is illustrated in figure 2.4.  
 







Figure 2.4 Principle behind cell migration assay. Cells in the front end of the scratch 
differentially express genes involved in cell motility, migration, and wound healing (figure 
reproduced with permission).86 
2.12 Cell Viability Assay 
Cell viability was evaluated using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay. Cells were seeded at a density of 5,000 per well in 
96-well plates containing 90 μl of full media for 24 h. Cells were then treated inhibitors for 
72 hours. After 72 hours, 10 μL of MTT (Acros, Cat. No. 298-93-1) solution (5 mg/ml in 
phosphate-buffered saline, PBS) was added to each well. The plate was incubated at 
37°C and 5% CO2 for 3 hours. After removal of the MTT solution via aspiration, 100 μl of 
DMSO was added to the wells for 10 minutes under agitation to dissolve the formazan 
crystals. Absorbance was measured at a wavelength of 570 nm using Wallac 1420 
software on a Perkin Elmer 1640 multilabel counter. Results are represented as cell 







2.13 Synergy Calculation 
Data from combination experiments were analyzed using the CompuSyn (v1.4) synergy 
software. Individual concentration response graphs of SC-1-151 in combination with JQ-
1 or LBH-549 were compared to 1:1 combination ratio. Combination indices (CI) < 1 and 
fraction affected (Fa) > 50% were considered synergistic. 
 
2.14 Statistical Analyses 
Two-tailed Student’s unpaired t-test was used in to analyze data that involved a 
comparison between treated (diphenylamine derivatives) and control (DMSO) groups 
(fold change, E-cadherin and spindle index). If p-values were below 0.05, differences 
were considered significant. Data represent ± SEM of at least three independent 
experiments. One-way analysis of variance (ANOVA) with Bonferroni post-hoc correction 
was used to examine concentration-dependent effect of the inhibitors on cell viability, 
proliferation, spheroid viability, and cell migration. Two-tailed Pearson correlation analysis 
and linear regression was used for correlation experiment. Statistical analyses were 











Chapter 3: Novel diphenylamine analogs inhibit MEK1/2 and MEK5 pathways, 
induce a mesenchymal to epithelial transition, and decrease spheroid formation, 
cell migration, and proliferation in triple-negative and tamoxifen-resistant breast 
cancer cells 
3.1 Introduction 
Triple negative breast cancers (TNBC) account for about 13-15% of total breast 
cancer cases.87 TNBCs are associated with poor prognoses and patient outcomes, and 
a high frequency of relapse. About 70% of breast cancer patients are diagnosed with ER-
positive breast cancer. These patients can be treated with ER-antagonists, such as 4-
Hydroxytamoxifen (4-OHT). However, the incidence of developing tamoxifen-resistance 
(TAMR) is high.88 Tamoxifen-resistance is also associated with gain of a mesenchymal 
phenotype due to β-catenin phosphorylation.89 TNBCs and TAMR cancers have a 
mesenchymal phenotype. Mesenchymal cells are migratory and invasive, which leads to 
secondary tumor formation or metastasis. Metastasis is the leading cause of death in 
cancer, and there are currently no treatments that effectively inhibit metastasis. 
Therefore, there is a dire need of targeted therapy for TNBCs and TAMR cancers.  
Mitogen Activated Protein Kinase (MAPK) pathways are important regulators of 
cell cycle and differentiation and the MEK1/2 and MEK5 MAPK signaling pathways are 
emerging targets for drug discovery. The MEK5-ERK5 pathway is an important 
therapeutic target in many cancers as it has been shown to regulate tumor growth and 
metastasis.90 Moreover, activation of the MEK5-ERK5 pathway, in response to inhibition 






inhibitors.91 MEK1/2 inhibitors trametinib and cobimetinib are FDA-approved for the 
treatment of NSCLC and melanomas; however, MEK5/ERK5 pathway inhibitors are only 
currently used as experimental tools. Our research interests include the development of 
selective novel pharmacological inhibitors of the MEK5-ERK5 pathway.  
Activation of MAPK results in phosphorylation of downstream targets ERK1/2 and 
ERK5, which can activate gene transcription of epithelial to mesenchymal transition 
(EMT) regulators such as ZEB1, Snail, and Vimentin.90, 92 EMTs play an instrumental role 
in cancer metastases.93-94 Therefore, inhibition of EMT is emerging as a target to 
attenuate the aggressive characteristics of cancer cells. Induction of the mesenchymal to 
epithelial transition (MET), the reverse of EMT, by small molecules, represents a practical 
and viable approach for treating the cancers which have a mesenchymal phenotype. 
While small-molecule kinase inhibitors mostly target the ATP-binding pocket, several 
novel diphenylamine derivatives were synthesized to target an allosteric site of MEK5 
(Figure 3.1 A).83 Allosteric inhibition of kinases may offer reduced resistance and greater 
kinase selectivity.95   
While the kinase domain of ERK1/2 and ERK5 proteins share about 60% 
sequence homology, ERK5 differs from ERK1/2 in its N-terminal domain, which harbors 
the nuclear localization sequence, and a unique allosteric binding pocket (Figure 3.1 A-
B). Novel MEK5 pathway inhibitors were synthesized by making structural modifications 
of the lead MEK1/2 inhibitor, PD325901. Compound 1, a dual MEK1/2 and MEK5 
inhibitor, was identified to target the EMT axis in MDA-MB-231 cells (Figure 3.2). The 






90% of high CD44+/CD24−/low stem cells,96 and has high expression of mesenchymal 
markers including vimentin, SNAIL, SLUG, and ZEB1.  
 
Figure 3.1: Drug discovery. A. ATP and Type III binding sites of the MEK1 crystal 
structure (PDB ID:3EQC) superimposed on a homology model of MEK5. ATP is shown 
as space filling and compound 1 is shown as a stick representation in the proposed type 
III binding site. B. Phylogram analysis of MEK isoforms; MEK5 is most closely related to 






Structural variants of compound 1 were synthesized to identify the functional 
groups responsible for induction of MET. We examined two experimental endpoints to 
quantify the activity of diphenylamine derivatives for a inducing mesenchymal to epithelial 
transition in MDA-MB-231 cells after treatment with structural analogs of compound 1: (i) 
upregulation of the epithelial marker E-cadherin examined via western blotting and (ii) 
phenotypic switch from mesenchymal to epithelial as indicated by a decrease in spindle 
index (SI) and an increase in % cells with SI<3. The lead molecule, compound 1, was 
found to decrease spheroid formation, cell migration, and cell proliferation in TNBC (MDA-
MB-231 and BT-549) and tamoxifen-resistant (TAMR) MCF-7 breast cancer cells. 
Compound 1 also decreased ZEB1, Snail, SOX2, and Vimentin (mesenchymal and stem 







Figure 3.2. Compound 1 (SC-1-151), a dual ERK1/2 and ERK5 inhibitor induces a 
phenotypic switch in MDA-MB-231 cells. (A.) Structure of Compound 1. (B.) 
Compound 1 inhibits ERK1/2 and ERK5 phosphorylation in MDA-MB-231 cells. Data 
represent the +/- SEM of three different experiments determined by two-way ANOVA with 
the Bonferroni post hoc test. *p<0.05; **P<0.01; ***P<0.001; ****P<0.0001; vs untreated 
respective control group determined; #P<0.001, ####P<0.0001; vs untreated control at 0 
hour determined by two-way ANOVA with the Bonferroni post hoc test. (C.) Compound 1 
was serendipitously identified to induce a phenotypic switch from mesenchymal to 
epithelial in MDA-MB-231 cells.  
 
3.2 Hypothesis: Novel diphenylamine analogs will induce MET and decrease spheroid 
formation, cell migration, and proliferation in triple-negative and TAMR breast cancer 
cells.  
3.3 Results: 
3.3.2 Structure-activity relationship of novel diphenylamine analogs for MET 
induction:  
MDA-MB-231 cells were treated with the diphenylamine structural variants (Figure 
3.3) at a concentration of 1 μM for 5 days. Increase in E-cadherin protein expression and 
change in morphology from mesenchymal to epithelial were the primary endpoints to 
study the effect on MET. E-cadherin expression order for amide variations at R1 (Figure 
3.3) was NHCH3 (2) > NH2 (1) > 4-Boc-piperazine (16) > piperazine (15) > N(CH3)2 (5) 
> N(C2H5)2 (4) > NHC2H5 (3) > N(CH3)C2H4N(CH3)2 (17) > 4-methylpiperazine (13; 
Table 3.1) at R1. Compounds 1, 2, 15, and 16 caused a >9-fold increase compared to 
DMSO. The 4-methyl piperazinyl analog 13 was 3-fold less active compared to compound 
1. Removal of the 4-methyl group led to a 3-fold improvement in E-cadherin induction 






Compounds 15 and 16 were equally effective as compound 1. The acid (7) was 2-fold 
less active, and ester 6 was about 5-fold less potent compared to 1. Both basic side chain 
amides (15) and neutral amides (1-5, 16) were active in inducing MET consistent with 
significant functional group tolerance attached to the amide group.  
Replacement of the R2 and R3 fluoro atoms with hydrogen atoms led to a >3-fold 
decrease in the E-cadherin expression (1 vs. 8). Similarly, replacing the R4 hydrogen with 
a methyl group led to a >3-fold reduction in the E-cadherin expression (1 vs. 9). 
Substituting the iodo atom (11) at R6 or the fluoro atom (12) at R5 with hydrogen results 
in a 3-fold decrease in E-cadherin expression as compared to 1. Removal of both the 
groups (10) did not increase E-cadherin expression. These data indicate that the fluorine 
atom at R5 and the iodine atom at R6 are essential for MET induction. The derivatives 
with substitutions at the R7 position were found to be inactive (19–21). The structural 
variations on the diphenylamine core, increase in E-cadherin expression, SI values, and 
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R2 R3 R5 R6 R7 
1 -NH2 -F -F -H -F -I -H 10.5 ± 3.5 0.012 2.2 ± 0.1 85.9 ± 3.4 
2 -NHMe -F -F -H -F -I -H 12 ± 4.6 0.002 2.7 ± 0.2 64.6 ± 0.4  
3 -NHEt -F -F -H -F -I -H 4.9 ± 1.9 0.001 2.5 ± 0.4 81.9 ± 7.8  
4 -N(C2H5)2 -F -F -H -F -I -H 6.1 ± 2.1 <0.0001 2.6 ± 0.2 67.5 ± 6.2 
5 -N(CH3)2 -F -F -H -F -I -H 7.6 ± 0.5 <0.0001 2.6 ± 0.2 73.1 ± 5.5 
6 -OMe -F -F -H -F -I -H 2.3 ± 0.7 0.015 2.9 ± 0.1 62.2 ± 2.4 
7 -OH -F -F -H -F -I -H 4.5 ± 2.05 0.009 2.8 ± 0.1 66.1 ± 6.4  
8 -NH2 -H -H -H -F -I -H 2.9 ± 1.4 0.062 3.3 ± 0.2 61.5 ± 5.1 
9 -NH2 -F -F -CH3 -F -I -H 2.8 ± 1.1 0.008 3.3 ± 0.4 52.4 ± 12 
10 -NH2 -F -F -H -H -H -H 1.3 ± 0.1 0.002 3.9 ± 0.3 29.7 ± 1.1 
11 -NH2 -F -F -H -F -H -H 4.3 ± 1.5 0.004 3.6 ± 0.1 44.9 ± 0.3 
12 -NH2 -F -F -H -H -I -H 3.1 ± 0.6 <0.0001 2.4 ± 0.1 83.1 ± 1.8 
13 4-methylpiperazine -F -F -H -F -I -H 3.4 ± 0.8 <0.0001 2.8 ± 0.1 70.7 ± 2.1 
14 4-methylpiperazine -F -F -H -F -H -H 1.1 ± 0.2 0.550 3.5 ± 0.1 41.3 ± 4.7 
15 -piperazine -F -F -H -F -I -H 9.1 ± 2.2 <0.0001 1.9 ± 0.2 86.3 ± 7.7 
16 4-Boc-piperazine -F -F -H -F -I -H 9.9 ± 4.1 <0.0005 2.8 ± 0.1 68.3 ± 4.7 
17 -N(CH3)C2H4N(CH3)2 -F -F -H -F -I -H 4.3 ± 3.3 0.048 3 ± 0.2 59.3 ± 6.1 
18 4-methylpiperazine -F -F -H -H -H -H 1.7 ± 0.47 0.0009 3.6 ± 0.1 55.8 ± 5.2 
19 4-methylpiperazine -F -F -H -H -H -N3 1.6 ± 0.90 0.2786 3.5 ± 0.2 47.4 ±2.9 
20 -NHEt -F -F -H -H -H -N3 0.77 ± 0.01 <0.0001 3.4 ± 0.2 47.1 ± 6.7 
21 4-methylpiperazine -F -F -H -H -H -Br 1.6 ± 0.88 0.2394 3.8 ± 0.2 37.6 ± 5.5 






Table 3.1: Effect of diphenylamine analogs on E-cadherin expression, spindle 
index, and % cells with S.I.<3 in MDA-MB-231 cells. MDA-MB-231 cells were treated 
with compounds 1-20 at 1μM concentration for 5 days. Data represent mean ± SEM. E-
Cadherin was normalized to a-tubulin, and fold change is compared to DMSO. One-way 
ANOVA with Bonferroni post-hoc comparison analysis was performed where the 
compounds were compared to the DMSO control and to each other; compounds 1 and 2 
were found to be statistically significant compared to the DMSO control group (P < 0.05). 
We missed significance across groups because there was large difference between the 
minimum and the maximum effect produced by the different compounds. Therefore, we 
switched to performing t-test and compared each compound individually to the DMSO 
control group. aData represent the ± SEM of three different experiments determined by 
unpaired two-tailed Student’s t-test (n = 3). 
 
Figure 3.4. Increase in E-cadherin expression significantly correlates with the 
percentage of cells with SI<3. A positive correlation between E-cadherin protein 
expression, compared to DMSO and an increase in percentage of cells with SI < 3 was 
observed. Data was analyzed by two-tailed Pearson correlation. The correlation 
coefficient (rP) and significance (p-value) are indicated on the scatter plot. 







MET is characterized by a morphological switch from a spindle-like phenotype to 
a cobblestone-like phenotype. To determine cell morphology, crystal violet staining was 
performed after 5 days of treatment with the diphenylamine analogs. To quantitate the 
phenotypic transition, spindle index (SI) was determined as the length to width ratio of 
each cell. Cells with a SI < 3 were considered epithelial.84  The compounds that led to an 
increase in E-cadherin protein expression also altered the morphology of MDA-MB-231 
cells from mesenchymal to epithelial, as measured by a reduction in the spindle index 
value. The compounds that increased E-cadherin expression by at least 3-fold and that 
displayed >50% of the cells with a SI < 3 were described as MET activators (Figure 3.4).  
The most potent MET activators from this series were analogs 1, 2, 15, and 16 
(Table 3.1, and Figure 3.4) inducing >9-fold increase in E-cadherin compared to DMSO 
(vehicle) and increasing % cells with SI < 3 by greater than 50%. Based on the primary 
endpoints of E-cadherin induction and spindle index, analogs 1 and 15 showed the best 
profile in increasing E-cadherin (10.5 and 9.1 fold increase, respectively vs. 1 with 
DMSO), percentage of cells with SI < 3 (85.9 and 86.3%, respectively vs. 30.5% with 
DMSO), and decreasing SI (2.2 and 1.9 fold, respectively vs. 4.2 with DMSO). Similar to 
diphenylamine analogs, tolfenamic acid and thyroid hormones contain two aromatic rings 
connected by a single heteroatom. Therefore, these compounds were evaluated for E-
cadherin expression and cell morphology. There was no increase in E-cadherin after 
treatment with NSAIDS or decrease in cell viability (Figure 3.5). The morphology of cells 







Figure 3.5 NSAIDS and thyroid hormones do not induce MET in MDA-MB-231 cells 
(A) E-Cadherin expression did not increase after treatment with NSAIDS. The compounds were 
treated for 5 days at 1μM concentration. (B.) NSAIDS did not inhibit cell viability.  Data 
represent the ± SEM of three different experiments. *P<0.05 vs control group determined 
by one-way ANOVA with the Bonferroni post hoc test.  
 
Analogs 1, 2, 15 and 16 were further tested in spheroid viability assays. Analog 18 
was included as a negative control. EMT can cause resistance to anchorage-independent 
death “anoikis,” and increase in spheroid-forming ability.97 To evaluate the effect of 
diphenylamines on spheroid formation, MDA-MB-231 cells were grown in ultra-low-
attachment plates (Figure 3.7A). Compound 1 significantly decreased spheroid viability 
compared to DMSO, compound 15, and compound 18 (Figure 3.7A and B). Therefore, 
we concluded that compound 1 was the best in-series and the effects of compound 1 









Figure 3.6. MDA-MB-231 cell morphology after treatment with diphenylamine analogs. MDA-MB-231 cells were 








    
   
                      
Figure 3.7. Compounds 1 and 15 decrease spheroid viability in MDA-MB-231 cells. 
(A) Spheroid formation in MDA-MB-231 cells after treatment with DMSO or compounds 
18, 15, and 1 for 7 days of treatment. (B) Quantification of the spheroid viability in MDA-
MB-231 cells, values indicate ± SEM of three experiments run in triplicate. ***p < 0.001, 
****p < 0.0001 vs. control group, ###p < 0.001 compound 1 vs. compound 18 #p < 0.05 
compound 1 vs. compound 15 determined by one-way ANOVA with the Bonferroni post 





3.3.4 Compound 1 increases E-cadherin and decreases mesenchymal markers in 
TNBC and TAMR cells 
Next, we wanted to examine the effect of the lead compound on more EMT 
markers, models, and in functional assays. We included another TNBC cell line BT-549 
and TAMR MCF-7 cells with a mesenchymal phenotype. When compared to the epithelial 
phenotype of parental MCF-7 cells, TAMR MCF-7 cells do not express E-cadherin (Figure 
3.8). These observations were consistent with previous studies, which have shown that 
tamoxifen resistance leads to EMT in MCF-7 cells.98-99 MDA-MB-231, BT-549, and TAMR 
MCF-7 cells were treated with compound 1 (Figure 3.9) for 5 days and the lysates were 
collected for western blotting. EMT markers, including the epithelial marker E-cadherin, a 
downstream target of ERK5, fos-related antigen (FRA-1), and mesenchymal markers 
ZEB1, vimentin, and snail were evaluated in TNBC and TAMR MCF-7 cells. Compound 
1 attenuated the expression of vimentin and stemness marker SOX2 in cells that 
underwent MET (Figure 3.9B-C). 
 
Figure 3.8. Tamoxifen resistance is associated with EMT in ER+ MCF-7 cells. (A) 
Cell morphology of WT and TAMR MCF-7 cells. (B) E-cadherin expression in TAMR MCF-





Compound 1 increased E-cadherin expression, decreased ZEB1, Snail, and FRA-
1 activation in MDA-MB-231, BT-549, and TAMR MCF-7 cells (Figure 3.9A). Compound 
1 decreased vimentin expression in MDA-MB-231 and TAMR MCF-7 cells, but not in BT-








Figure 3.9. Compound 1 decreases mesenchymal markers and increases E-
cadherin expression in breast cancer cells (A) Compound 1 decreases EMT markers, 
FRA-1 activation, and induces E-cadherin in TNBC and TAMR MCF-7 cells. (B) 
Compound 1 attenuates vimentin expression in MDA-MB-231 cells. (C) Compound 1 
attenuates SOX2 expression in MDA-MB-231 cells. 
 
3.3.5 Lead compound 1 decreases cell migration, colony formation, and cell 







Figure 3.10. Compound 1 decreases cell migration, colony formation, and cell 
proliferation in MDA-MB-231 cells. (A, B) Wound closure was measured as a 
percentage of untreated DMSO control group. *p < 0.05 vs. DMSO control group 
determined by one-way ANOVA with the Bonferroni post hoc test. (C) Compound 1 
inhibited MDA-MB-231 colony formation after 14 days of treatment in a concentration-
dependent manner. Data represent ± SEM of experiments run in triplicate, *p < 0.05; **p 
< 0.01 vs. DMSO control group determined by one-way ANOVA with the Bonferroni post 
hoc test. (D) Immunofluorescence staining of Ki67, Hoechst, and a-tubulin in MDA-MB-
231 cells treated with DMSO or compound 1 (1μM), for 72 hours, scale bar 200μm. (E) 
Ki67+ cells decreased with increasing concentrations of compound 1. (F) Decrease in 
Hoechst+ cells with increasing concentrations (0.1, 1, 10μM) of compound 1. (G) The 
proliferative fraction calculated as the ratio of Ki67+ cells to Hoechst+ cells at increasing 
concentration. Data represent ± SEM of three different experiments. **p < 0.01; ***p < 
0.001 vs. control group determined by one-way ANOVA with the Bonferroni post hoc test. 





Treatment with compound 1 produced a concentration-dependent reduction in cell 
migration (Figure 3.10A-B), and colony formation (Figure 3.10C) in MDA-MB-231 cells. 
Immunofluorescence staining for Ki67 and Hoechst was performed to evaluate cell 
proliferation in MDA-MB-231 cells. Compound 1 significantly decreased the number of 
Ki67+ and Hoechst+ cells (Figure 3.10D-E) and the proliferative fraction determined as 
the number of Ki67+/ number of Hoechst+ cells (Figure 3.10F). The effects of compound 
1 were also evaluated on spheroid formation, cell migration, and proliferation in BT-549 
TNBC cells and TAMR MCF-7 ER+ breast cancer cells.  
3.3.6 Compound 1 inhibits spheroid formation, cell migration, and proliferation in 
BT-549 and TAMR-MCF-7 cells. 
BT-549 and TAMR-MCF-7 cells were treated with 0.1, 1, and 10 μM concentrations 
of compound 1. Compound 1 produced a concentration-dependent decrease in spheroid 
viability after 7 days in BT-549 cells (Figure 3.11A-B) and TAMR MCF-7 cells (Figures 
3.11C-D). At 1 μM concentration, compound 1 decreased spheroid viability by 51.55 and 
72.91% in BT-549 and TAMR MCF-7 cells, respectively. Compound 1 produced a 
concentration-dependent decrease in cell migration and proliferation in BT-549 cells 
(Figures 3.12A and C). There was a 67.9% reduction in cell proliferation at 10μM 






Figure 3.11. Compound 1 inhibits spheroid viability in BT-549 and TAMR MCF-7 
cells. (A) Spheroid formation in BT-549 cells after treatment with DMSO or compound 1 
at 1μM concentration for 7 days, scale bar 1,000μm. (B) Quantification of the spheroid 
viability in BT-549 cells after treatment with compound 1 at increasing concentrations (0.1, 
1, 10 μM) after 7 days of treatment, data represents ± SEM *p < 0.05; ***p < 0.001 vs. 
control group determined by one-way ANOVA with the Bonferroni post hoc test in BT-549 
cells. (C) Spheroid formation in TAMR MCF-7 after treatment with DMSO or compound 1 
at 1μM concentration for 7 days, cells scale bar 1,000μm. (D) Quantification of the 
spheroid viability after treatment with compound 1 at increasing concentrations (0.1, 1, 
10 μM) after 7 days of treatment in TAMR MCF-7 cells, values indicate ± SEM of three 
experiments run in triplicate. *p < 0.05; ***p < 0.001 vs. control group determined by one-
way ANOVA with the Bonferroni post hoc test.  
 
In TAMR MCF-7 cells, compound 1 produced a concentration-dependent 
decrease in cell migration (Figure 3.13A-B).  Additionally, treatment with compound 1 
significantly decreased the number of Ki67+ (Figure 3.13D) and Hoechst+ (Figure 3.13E) 





Figure 3.12. Compound 1 inhibits cell migration and proliferation in BT-549 cells. 
(A) Wound closure was measured after treatment with increasing concentrations (0.1, 1, 
10μM) of compound 1. The data is presented as a percentage of untreated DMSO control 
group. *p < 0.05 vs. control group determined by one-way ANOVA with the Bonferroni 
post hoc test (BT-549 cells). Compound 1 inhibits cell proliferation in BT-549. (C) 
Immunofluorescence staining of Ki67, Hoechst, and a-tubulin in BT-549 cells treated with 
DMSO or compound 1 (1μM), for 72 hours, scale bar 200μm. (B) Ki67+ cells decreased 
with increasing concentrations (0.1, 1, 10μM) of compound 1. (C) Decrease in Hoechst+ 
cells with increasing concentrations (0.1, 1, 10μM) of compound 1. (D-F) The proliferative 
fraction calculated as the ratio of Ki67+ cells to Hoechst+ cells at increasing 
concentrations (0.1, 1, 10μM) of compound 1. Data represent ± SEM of three different 
experiments. *p < 0.05 vs. control group determined by one-way ANOVA with the 






Figure 3.13. Compound 1 inhibits cell migration and proliferation in TAMR MCF-7 
cells.  (A) Wound closure was measured after treatment with increasing concentrations 
(0.1, 1, 10μM) of compound 1. The data is presented as a percentage of DMSO control 
group. *p < 0.05; ***p < 0.001 vs. control group determined by one-way ANOVA with the 
Bonferroni post hoc test (TAMR MCF-7 cells). Compound 1 inhibits cell proliferation in 
TAMR MCF-7 cells (C) Immunofluorescence staining of Ki67, Hoechst, and a-tubulin in 
TAMR MCF-7 cells treated with DMSO or compound 1 (1 μM), for 72 hours, scale bar 
200 μm. (D) Ki67+ cells decreased with increasing concentrations (0.1, 1, 10 μM) of 
compound 1. (E) Decrease in Hoechst+ cells with increasing concentrations (0.1, 1, 10 
μM) of compound 1. (TAMR MCF-7 cells) (F) The proliferative fraction calculated as the 
ratio of Ki67+ cells to Hoechst+ cells at increasing concentrations (0.1, 1, 10 μM) of 
compound 1 (TAMR MCF-7 cells). Data represent ± SEM of three different experiments. 
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 vs. control group determined by one-
way ANOVA with the Bonferroni post hoc test. 
 
3.4 Discussion 
Our findings suggest that at the R1 position the diphenylamine core, amides 
(primary, secondary, and tertiary) induced E-cadherin to a greater fold compared to ester 
(6) or acid (7). The R1 position showed tolerance toward steric bulk and charge. At R2 
and R3, the removal of both fluoro groups reduced the E-cadherin expression by 3.5 fold 
(8 vs. 1). We speculate that the electron-withdrawing fluorine atoms either polarize the 




interactions and/or ion-dipole interactions) or the fluorine atom may act as hydrogen bond 
acceptor (HBA) (32). At R4 position, the replacement of the hydrogen atom (1) with a 
methyl group (9), led to a 4-fold reduction in E-cadherin expression. These data suggest 
that the R4 hydrogen participates in an intramolecular hydrogen bond with the carbonyl 
group attached to R1, forming a conformation favoring MET. The N-methyl group of 
analog 9 may disrupt the intramolecular hydrogen bond, leading to the corresponding 
decrease in E-cadherin expression.  
By substituting the fluorine at R5 and iodine at R6 with hydrogen atoms, there was 
no increase in E-cadherin expression (analog 10 vs. 1). We speculate that the fluoro 
group at R5 may: a) decrease the pKa of the R4 hydrogen making it a better hydrogen 
bond donor to facilitate MET induction, and/or b) increase the lipophilicity of the molecule; 
improving hydrophobic interactions with the biological target(s) (33, 34).  
The iodo group at R6 is a large group, which can undergo hydrophobic interactions 
and/or can form a halogen bond. At R7 position all the three analogs (19- 21) were 
inactive in inducing MET. An important contributing factor could be that these compounds 
do not have any substitutions at R5 and R6 positions. Moreover, they did not possess a 
free NH2 group at R1, which may contribute to their inability to induce MET. Overall, our 
initial structure-activity study suggests that different substitutions at R1 are tolerated and 
this position can be exploited toward improving potency or deducing the molecular target 
of diphenylamines. Removal/change of substituents at R2-R7 positions are not tolerated. 
Therefore, they may represent the minimum pharmacophore required for MET activity. 
There was a positive correlation between increase in E-cadherin expression and the 




also suggests that spindle index measurement could be a reliable quantitative analysis 
for cells that undergo morphological transitions. 
NSAIDS (tolfenamic acid, sulindac, and meloxicam) and thyroid hormones 
(triiodothyronine and thyroxine) bear structural similarity to the diphenylamine 
compounds, but they did not induce MET in MDA-MB-231 cells (Figure 3.5). One reason 
could be both NSAIDs and thyroid hormones do not have the minimum pharmacophore 
required for inducing MET. Also, the in-house diphenylamines inhibit MEK1/2 and MEK5; 
since the biological targets of the two drug classes under study are different, this may 
explain why NSAIDS and thyroid hormones did not induce MET.  
MDA-MB-231 cells cultured in low-attachment plates were examined to determine 
the effect of compounds 1, 15, and 18 on spheroid formation. The selection of compounds 
was made based on their ability to induce MET: low (compound 18)—high (compounds 
1 and 15) and differences in their structures (primary vs. tertiary amides at R1). Two-way 
ANOVA with Bonferroni post-hoc test revealed that compound 1 was the most effective 
in inhibiting spheroid growth. One of the reasons why compound 1 was more effective is 
because compound 1 is a dual MEK1/2 and MEK5 inhibitor, but compounds 15 and 18 
inhibit MEK1/2 and MEK5, respectively.83 Therefore, the effects of compound 1 were 
examined on cell migration and proliferation.  Moreover, the effect of compound 1 was 
characterized in two additional breast cancer cell models, which have a mesenchymal 
phenotype: TNBC cell line BT-549 and tamoxifen-resistant MCF-7 cell line.  
Since EMT triggers cell migration and motility, the scratch assay/ wound closure 
assay was performed to examine cell migration. Cells at the border of the wound are 




that undergo MET may re-acquire the proliferative potential to promote metastatic 
colonization.100 Therefore, we examined the effect of compound 1 on cell proliferation. 
Compound 1 significantly decreased cell migration and proliferation in diverse breast 
cancer models. Compound 1 also decreased spheroid formation in MDA-MB-231, BT-
549 TNBC, and TAMR MCF-7 cells including spheroid formation, cell migration, and cell 
proliferation. In summary, to our knowledge, this is the first time that novel inhibitors of 
MEK1/2 and/or MEK5 pathways were examined to influence EMT reversal in triple-
negative and tamoxifen resistant breast cancers. Compound 1, a novel dual MEK1/2 and 
MEK5 inhibitor was effective in inducing MET in diverse breast cancer subtypes, 
decreasing proliferation, migration, and spheroid formation.  
In conclusion, EMT is a crucial process for cancer progression and metastases. 
Therefore, a reversal of the EMT to induce an MET may decrease metastases to allow 
targeting of the less aggressive epithelial cancer cells in situ. Through analog-based drug 
design, analogs that potentiate MET were discovered. Compound 1 was identified as the 
lead, as treatment with this compound increased E-cadherin expression and caused 
morphological change from mesenchymal to epithelial phenotype. Moreover, compound 
1 attenuated the migratory and proliferative properties of TN and TAMR breast cancer 
cells. In the next chapters, we will discuss about independent and overlapping functions 
of ERK1/2 and ERK5 pathways on EMT/MET, nuclear localization of ERK, and migration, 
proliferation, and spheroid formation. Moreover, several combination strategies of 






Chapter 4: Targeting the ERK5 and/or ERK1/2 pathways reverses EMT, decreases 
proliferation, migration, and spheroid formation in triple-negative and tamoxifen-
resistant breast cancer cells 
4.1 Introduction 
Metastases account for ~90% of cancer related human deaths.101 An increasing 
body of evidence suggests that activation of ERK1/2 and ERK5 signaling is a marker for 
node metastases and a predictor of poor responses to hormone therapy such as 4-
OHT.102-104 Moreover, activation of intracellular signaling pathways, such as the ERK 
MAPK pathways, has been shown to mediate tumorigenesis in TNBCs and tamoxifen 
resistant breast cancers.105-106 For example, ERK1/2 activation is known to mediate EMT 
in several cancer models18, 92, 107-108,  and overexpression of the newest member of the 
MAPK family, ERK5, induces EMT and hormone-independent growth of breast cancer.104 
Although activation of the ERK1/2 and ERK5 pathways have been shown to mediate 
EMT, the effect of ERK1/2 and ERK5 inhibition on inducing MET, the reverse of EMT, is 
poorly understood in cancer.  
To identify the link between MAPK pathways and EMT, MAPK3 (ERK1), 
MAPK1(ERK2), and MAPK7 (ERK5) gene expression was correlated with EMT markers 
CDH1, ZEB1, or VIM in tumors derived from TNBC patients using publicly available 
datasets. Additionally, overall survival in patients with inflammatory breast cancer was 
plotted against ERK1, ERK2, or ERK5 gene expression using publicly available datasets. 
TNBCs account for about 40% of all inflammatory breast cancers.109 
We hypothesize that inhibition of the ERK1/2 and ERK5 pathways is a relevant 




ERK1/2 and ERK5 pathways on the MET using pharmacological inhibitors of MEK1/2 and 
ERK5, trametinib and XMD8-92, respectively. Since the location-specific roles of ERK1/2 
and ERK5 with respect to EMT are less well-understood, we examined the effect of 
XMD8-92 and trametinib on nuclear localization of ERK1/2 and ERK5. To validate the 
inhibitor data, the effect of lentivirus-mediated activation or inhibition of ERK1/2 and ERK5 
pathway components on the MET was examined. Cell morphology and protein expression 
of epithelial and mesenchymal markers, E-cadherin and ZEB1 were examined and 
activation of ERK1/2, ERK5, and RSK, a downstream target of MAPK signaling, were 
evaluated. The effects of XMD8-92 and trametinib were evaluated on cell migration and 
cell proliferation in MDA-MB-231, BT-549 TNBC cells, and tamoxifen-resistant (TAMR) 
MCF-7 breast cancer cells. Moreover, TU-BcX-4IC patient-derived primary TNBC cells 
were included to enhance the translational relevance of our study. 
4.2 Hypothesis 
Inhibition of ERK1/2 and/or ERK5 pathways will induce MET and decrease cell migration, 
proliferation, and spheroid formation in TNBC and TAMR breast cancer cells. 
4.3 Results 
4.3.1       ERK1, ERK2, and ERK5 expression correlates with EMT markers and is 
associated with poor patient survival in breast cancer 
 Since the effect of ERK1/2 and ERK5 pathways on EMT is less well-understood in 
TNBCs, we first used publicly available datasets from Purrington, K. S. and colleagues110 
to correlate MAPK3 (ERK1), MAPK1 (ERK2), or MAPK7 (ERK5)  gene expression with 




from African-American TNBC patients (Figure 4.1). There was a moderate to strong 
correlation between MAPK3, MAPK1, and MAPK7 with mesenchymal markers ZEB1 and 
vimentin. Using Kaplan-Meier survival analysis to examine the relationship between 
ERK1/2/5 expression and patient survival in inflammatory breast cancer (public datasets 
from Bertucci et al.109), MAPK3, MAPK1, or MAPK7 gene expression were found to be 
associated with poor patient survival (Figure 4.2). Overall, these data suggest that ERK1, 





Figure 4.1 Correlation of ERK1, ERK2, or ERK5 with EMT markers in tumors derived 
from TNBC patients. Gene correlation between (A) MAPK3(ERK1), (B) MAPK1(ERK2), 
or (C) MAPK7 (ERK5) and EMT markers CDH1, ZEB1, or VIM was plotted using R2: 
Genomics analysis and visualization platform (https://hgserver1.amc.nl/cgi-
bin/r2/main.cgi). Datasets were exported from Tumor Breast (triple negative) - Purrington 
- 226 - rma_sketch - hugene21t. 
 
 
Figure 4.2 MAPK3, MAPK1, and MAPK7 expression correlates with poor patient 
survival in breast cancer. Disease free survival was analyzed using R2: Genomics 
analysis and visualization platform (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi). 
Datasets were exported from Tumor Breast (MDC) Bertucci - 266 - MAS5.0 - u133p2. 
 
4.3.2 Pharmacological inhibition of the ERK1/2 and/or ERK5 pathways induces MET 
in TNBC and TAMR breast cancer 
Since ERK1, ERK2, and ERK5 were identified as important targets in breast 
cancer and their gene expression was found to correlate with EMT markers, 
pharmacological inhibitors of these pathways were utilized to examine their effect on 
MET, the reverse of EMT. MDA-MB-231, BT-549, TU-BcX-4IC TNBC, and TAMR cells 
were treated with increasing concentrations of XMD8-92, an ERK5 and BRD4 inhibitor, 




the morphology of the breast cancer cells was examined. Trametinib induced a 
morphological switch from mesenchymal to epithelial in all the cell lines, while XMD8-92 
only induced this morphological change in MDA-MB-231 cells (Figures 4.3).  
To confirm the morphological switch, we examined the expression of the epithelial 
and mesenchymal markers, E-cadherin and ZEB-1, respectively. Trametinib increased 
E-cadherin expression in MDA-MB-231, BT-549, TU-BcX-4IC, and TAMR cells and 
decreased ZEB-1 expression in MDA-MB-231 and TU-BcX-4IC cells.  XMD8-92 (10uM) 
decreased the expression of E-cadherin and ZEB1 only in MDA-MB-231 cells (Figure 
4.3A). WT-MCF-7 epithelial cells were included as a control to study EMT. Treatment of 
the WT-MCF-7 cells with XMD8-92 or trametinib did not alter cell morphology or E-
cadherin expression (Figure 4.4A, B). p-P90RSK, a downstream target of MAPK pathway 
was undetected in WT-MCF-7 cells, indicating that RSK activation may be a major event 
in regulating EMT associated with tamoxifen-resistance (Figure 4.4C). Cells that undergo 
EMT may exhibit a complete cadherin switch, which is characterized by a complete loss 
of E-cadherin; however, partial EMT state is characterized by co-expression of epithelial 
and mesenchymal markers.111 The extent of MET induced by the inhibitors was 
determined by examining the correlation between E-cadherin and ZEB1 expression 
(Figure 4.5). A greater than 3-fold change in protein expression is indicative of a 
significant difference. Therefore, treatment that induced E-cadherin expression by greater 
than 3-fold and decreased ZEB1 by greater than 0.3-fold was determined to induce a full 
MET, whereas treatment that induced a 3-fold increase in E-cadherin expression or 0.3-




231 and TAMR MCF-7 cells at low and high doses, whereas it induced a partial MET in 






Figure 4.3 ERK1/2 and ERK5 pathway inhibition induces MET in TNBC and TAMR MCF-7 cells. Cells were treated with XMD8-
92 and trametinib at increasing concentrations for 72 hours. Cell morphology (20X magnification) and EMT markers E-cadherin and 
ZEB1 were examined in (A) MDA-MB-231, (B) BT-549, (C) TU-BcX-4IC, and (D) TAMR MCF-7 cells. Data represent the ± SEM of 
three different experiments for each inhibitor compared to DMSO control. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 vs DMSO control 







Figure 4.4 Evaluation of cell morphology, E-cadherin and p-P90RSK levels in WT-
MCF-7 cells. (A) Kinase inhibitors do not alter the phenotype (20X magnification) or (B) 
E-cadherin expression in ER+ MCF-7 epithelial cells. (C) p-P90RSK was not detected in 





Figure 4.5 Correlation to determine extent of MET induced by trametinib or XMD8-92. (A) 
MDA-MB-231, (B) BT-549, (C) TU-BcX-4IC, and (D) TAMR MCF-7 cells.   
4.3.3 Role of kinases in MET 
ERK1/2 and ERK5 pathways are important regulators of EMT. To examine a role 
for the MAPK pathways in MET, ERK1/2, ERK5, and RSK activation in MDA-MB-231, 
BT-549, TU-BcX-4IC and TAMR MCF-7 cells were examined after 72 hours of treatment 
of trametinib or XMD. As expected, trametinib significantly decreased ERK1/2 and RSK 
phosphorylation in the panel of breast cancer cell lines. Interestingly, trametinib (0.1 μM) 
decreased ERK5 phosphorylation in MDA-MB-231 cells. XMD8-92 decreased ERK5 
phosphorylation in MDA-MB-231 cells by 40% and 65% at 1 and 10 μM concentrations, 




BT-549, TU-BcX-4IC, and TAMR cells, (Figure 4.6 B, C, D). XMD8-92 decreased RSK 
phosphorylation by ~ 40% at all concentrations in MDA-MB-231 cells and at the lowest 
concentration in BT-549 cells. Overall, these findings that ERK1/2 and ERK5 activities 
are differentially modulated by kinase inhibitors, indicating involvement of crosstalk 
mechanisms between these pathways in diverse breast cancer models.  
Cells were also treated with trametinib and XMD8-92 for shorter time points to 
determine the effect of the inhibitors on EGF-mediated stimulation of the MAPK pathways. 
This is a relevant assay to examine specificity of kinase inhibitors. Following serum 
starvation for 18-24 hours, cells were treated with an inhibitor for 30 minutes, and then 
with epidermal growth factor (EGF) for 15 minutes. XMD8-92 significantly decreased 
ERK5 phosphorylation, as compared to DMSO+EGF treatment control in MDA-MB-231 
and TAMR MCF-7 cells. Interestingly, in MDA-MB-231 and TAMR-MCF-7 cells, XMD8-
92 had the opposite effect on ERK1/2 phosphorylation, such that ERK1/2 phosphorylation 
was increased in BT-549 cells and decreased in TAMR-MCF-7 cells. In BT-549 and TU-
BcX-4IC cells, XMD8-92 did not significantly alter ERK5, ERK1/2, or RSK phosphorylation 
induced by EGF. As expected, trametinib, a MEK1/2 inhibitor significantly decreased 
activation of downstream targets of MEK1/2: ERK1/2 and RSK, in a dose-dependent in 
response to EGF stimulation in BT-549, TU-BcX-4IC, and TAMR MCF-7 cells (Figure 
4.7). However, trametinib significantly decreased EGF-mediated ERK1/2, ERK5, and 
RSK phosphorylation in a dose-dependent manner in MDA-MB-231 cells (Figure 4.7). 
These data indicate that trametinib is a dual inhibitor of ERK1/2 and ERK5 pathways in 
MDA-MB-231 cells, but not in BT-549, TU-BcX-4IC, and TAMR MCF-7 cells. These data 





Figure 4.6 Western blot analysis of MAPK downstream targets pERK5, pERK1/2, and p-
P90RSK in TNBC cells. (A) MDA-MB-231, (B) BT-549, (C) TU-BcX-4IC, and (D) TAMR MCF-7 
cells. Data represent the ± SEM of three different experiments for each inhibitor compared to 
DMSO control. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 vs DMSO control group determined 







Figure 4.7 Evaluation of kinase inhibition under EGF stimulation. Cells were serum starved 
for 18-24 hours and treated with the respective inhibitors for 30 minutes. EGF was added at a 
100ng concentration for 15 minutes and western blot was performed on the lysates collected for 
analysis of ERK5, ERK1/2, and P90RSK activation in (A) MDA-MB-231, (B) BT-549, (C) TU-BcX-
4IC, and (D) TAMR MCF-7 cells. Data represent the ± SEM of three different experiments for 
each inhibitor compared to DMSO control. *p<0.05; **p<0.01; ****p<0.0001 vs DMSO control 
group determined by one-way ANOVA with the Bonferroni post hoc test. 
 
4.3.4 Effects of XMD8-92 and trametinib on cell migration and proliferation in breast 
cancer 
EMT is known to promote cell migration via downregulation of cell-cell adhesion 




plates using a pipette tip. Wound closure was measured after treatment with DMSO or 
inhibitors to determine the efficacy of MAPK inhibitors on cell migration. XMD8-92 
decreased cell migration in MDA-MB-231 and TU-BcX-4IC cells at 10 μM concentration 
(Figure 4.8A and C). Trametinib significantly decreased cell migration in MDA-MB-231, 
BT-549, TU-BcX-4IC, and TAMR breast cancer cells (Figure 4.8A-D).  
Cancer cells have high proliferation rates. To determine this proliferative fraction, cells 
were stained with Ki67, a marker of proliferation. Proliferative fraction was calculated as 
the ratio of number of Ki67+ cells to Hoechst+ cells. XMD8-92 produced a significant 
decrease in proliferative fraction of MDA-MB-231, TU-BcX-4IC, and TAMR-MCF-7 cells 
(Figure 4.8E, G-H), but not in BT-549 cells (Figure 4.8F). Trametinib had no effect on the 






Figure 4.8.  XMD8-92 and trametinib differentially decrease cell migration and proliferation in diverse breast cancer subtypes. 
A) MDA-MB-231, (B) BT-549 cells, (C) TU-BcX-4IC, and (D) TAMR MCF-7 cells were treated with the kinase inhibitors and scratch 
assay was performed (20X magnification). Cell migration was measured as a percentage of DMSO control group. Cell proliferation 
assay was performed (E) MDA-MB-231, (F) BT-549, (G) TU-BcX-4IC and (H) TAMR MCF-7 (20X magnification). Data represent the ± 
SEM of three different experiments. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 vs. DMSO control group determined by one-way 




4.3.5 Trametinib decreases nuclear ERK5 in MDA-MB-231, but not in BT-549 cells 
ERK5 has a large C-terminal domain, which can facilitate its nuclear localization in 
response to growth factors or via autophosphorylation.113 ERK5 nuclear localization has 
been linked with increase in cell proliferation.114 However, there are no studies that relate 
the role of ERK5 localization to EMT. To examine the localization of ERK5 in TNBC with 
distinct kinase mutation profiles, we selected two cell lines from our previously studied 
cells: MDA-MB-231 are driven by a mutation in RAF leading to aberrant activation of the 
MEK1/2-ERK1/2 and MEK5-ERK5 pathways, and BT-549 cells are driven by a loss of 
function mutation in tumor suppressor phosphatase, PTEN, leading to subsequent 
activation of the PI3K-AKT pathway.  
MDA-MB-231 and BT-549 cells were treated with DMSO, 1 μM XMD, or 0.1 μM 
trametinib for 72 hours. ERK5 was found to be localized in the nucleus and cytosol, but 
active only in the nucleus of untreated MDA-MB-231 and BT-549 TNBC cells (Figure 4.9). 
While ERK1/2 were found in both the nucleus and cytosol, ERK1/2 expression was higher 
in the cytosol of the TNBC cells. In contrast to ERK5, ERK1/2 phosphorylation was noted 
only in the cytosol of untreated MDA-MB-231 and BT-549 cells. Surprisingly, XMD8-92 
did not decrease ERK5 activation in the nucleus of either cells. Trametinib decreased 
total and phosphorylated ERK5 in the nucleus of MDA-MB-231 cells (Figure 4.9A, B), but 
inhibited ERK5 only in the cytosol in BT-549 cells (Figure 4.9D). Trametinib significantly 
decreased ERK1/2 activation in the cytosol in MDA-MB-231 and BT-549 cells. Total 
ERK1/2 expression was not altered with either treatment in the cytosol of either cell line. 




contribute to the MET-inducing potential of trametinib in MDA-MB-231 cells. Future 







Figure 4.9 Effect of XMD8-92 and trametinib on ERK5 and ERK1/2 activation in the nucleus and cytoplasm. (A) MDA-MB-231 
nuclear fraction (B) MDA-MB-231 cytosolic fraction (C) BT-549 nuclear fraction (D) BT-549 cytosolic fraction. *p<0.05; ***p<0.001 vs 




4.3.6 Diverse and converging roles of MEK1 and MEK5 on EMT and kinase 
activation in TNBC cells 
To further examine the roles of the ERK1/2 and ERK5 pathways on MET, MDA-
MB-231 and BT-549 cells were treated with dominant negative (dn) and constitutively 
active (ca) lentivirus vectors of MEK1 and MEK5 (generous gift from Dr. Zhengui Xia). 
The cells were transiently co-infected with GFP tagged dnMEK1, dnMEK5, caMEK1, 
and/or caMEK5 lentivirus vectors, as indicated, for 96 hours. The morphology of infected 
cells was assessed via immunostaining for the cytoskeletal protein α-actinin (Figure 
4.10A). Cells that were infected with dnMEK1 or dnMEK5 alone and in combination 
displayed a phenotypic shift from mesenchymal to epithelial. Transfection with caMEK1 
or caMEK5 alone and in combination increased the mesenchymalization of MDA-MB-231 
and BT-549 cells (Figure 4.10A, C). Infection with dnMEK5 decreased ERK5 
phosphorylation by ~25% and transfection with caMEK1+caMEK5 significantly increased 
ERK5 activation in MDA-MB-231 cells (Figure 4.10B). There were no significant changes 
in ERK1/2 phosphorylation in MDA-MB-231 cells. In BT-549 cells, infection with dnMEK1 
and dnMEK5 did not significantly decrease ERK5 or ERK1/2 phosphorylation; however, 
transfection with caMEK1 or caMEK1+caMEK5 significantly increased ERK1/2 activation 













Figure 4.10. MEK1 and MEK5 activation mediates EMT in TNBC cells. (A, B) MDA-MB-231 and (C, D) BT-549 cells were treated 
with dnMEK5, dnMEK1, caMEK5, and caMEK1 alone and in combination as represented in the figure. The cells were incubated for 96 
hours. Immunofluorescence staining for α-actinin was performed to assess the morphology (40X magnification). The effect on ERK1/2 
and ERK5 activation was evaluated via western blotting. *p<0.05; **p<0.01 vs GFP control group determined by one-way ANOVA with 





4.3.7 MEK1 and MEK5 pathways regulate ZEB1 expression in TNBC cells  
To further understand the role MAPK pathways in the induction of MET, cell-
specific responses to lentivirus-mediated MEK1/2 and MEK5 pathway inhibition and 
activation on ZEB-1, a marker of mesenchymal cells, was examined. MDA-MB-231 and 
BT-549 cells infected with dnMEK1, dnMEK5, caMEK1, or caMEK5 lentivirus vectors 
alone and in combination were assessed for ZEB1 expression by immunofluorescence. 
MDA-MB-231 cells that were infected with dnMEK1, dnMEK5, and dnMEK1+dnMEK5 
vectors (GFP+ cells) had an epithelial phenotype and attenuated ZEB1 expression 
(Figure 4.11A). Conversely, while cells infected with caMEK1, caMEK5, and 
caMEK1+caMEK5 groups had a more pronounced mesenchymal morphology compared 
to GFP control, ZEB1 expression was not increased (Figure 4.11A). BT-549 cells that 
were infected with dnMEK1, dnMEK5, or dnMEK1+dnMEK5 appeared epithelial but had 
no reduction in ZEB1 expression (Figure 4.11B). caMEK1, caMEK5, or 
caMEK1+caMEK5-infected BT-549 cells had a more pronounced mesenchymal 






Figure 4.11 MEK1 and MEK5 activation mediates ZEB1 expression in TNBC cells. (A) MDA-MB-231 and (B) BT-549 cells were 
transfected with dnMEK5, dnMEK1, caMEK5, and caMEK1 alone and in combination as represented in the figure. The cells were 





Next, we determined if pharmacological inhibition of the MAPK pathways with 
trametinib could restore the epithelial phenotype and decrease mesenchymal cell 
markers following caMEK5 transfection in MDA-MB-231 and BT-549 cells. Cells were 
treated with 0.1 μM trametinib in the presence of GFP or caMEK5 lentivirus to examine 
the effects on cell morphology, E-cadherin, and ZEB1 expression. MDA-MB-231 cells 
treated with trametinib transitioned to an epithelial phenotype and had a reduction in 
ZEB1 expression (Figure 4.12) This reduction in ZEB1 was inhibited in cells that were 







Figure 4.12 Effect of trametinib+caMEK5 on TNBC cell morphology and ZEB1 expression. (A, B) MDA-MB-231 and 
(C, D) BT-549 cells were treated with GFP, Tra+GFP, caMEK5, and Tra+caMEK5 for 96 hours. Immunofluorescence 





Similar to the immunocytochemical data, caMEK5 inhibited the trametinib-mediated 
decrease in ZEB1 expression as determined by western blotting in MDA-MB-231 cells 
(Figure 4.13), but not in BT-549 cells (Figure 4.13). Interestingly, caMEK5 transfection 
did not increase the trametinib-mediated increases in E-cadherin expression in either 
TNBC cell line (Figure 4.13). Together our data suggest that targeting both ERK12 and 
ERK5 pathways induces MET in MDA-MB-231 cells but targeting ERK1/2 pathway alone 







Figure 4.13 Effect of trametinib+caMEK5 on E-cadherin and ZEB1 expression in TNBC cells. (A-D) MDA-MB-231 and 
(E-H) BT-549 cells were treated/infected with GFP, Tra+GFP, caMEK5, and Tra+caMEK5 for 96 hours. Western blotting for 




4.3.8 MEK1 and/or MEK5 activation reduces the ability of trametinib to decrease 
vimentin expression in MDA-MB-231 VIM RFP 2D and spheroid cell cultures. 
 
The effect of dual ERK1/2 and ERK5 pathway inhibition on MET was found to be 
most promising in MDA-MB-231 cells. Therefore, to strengthen the functional contribution 
of inhibiting the ERK1/2 and ERK5 pathways in MET, MDA-MB-231 VIM RFP cells, a new 
model for MET research, were infected with caMEK1 and/or caMEK5 in the presence of 
DMSO, trametinib, or XMD8-92. These cells have been transformed to constitutively 
express vimentin, a mesenchymal marker, via CRISPR-knock-in system and serve as a 
good model to study MET (ATCC). Vimentin expression was examined in 2D and 
spheroid cultures following treatment with caMEK isoforms in the presence or absence of 
the MAPK inhibitors. While treatment with XMD8-92 alone did not reduce vimentin 
expression in 2D cultures, treatment with trametinib moderately decreased vimentin 
expression, specifically in cells that underwent a MET as determined by examining 
morphology of GFP+ cells via microscopy (Figure 4.14). Treatment with caMEK1, 
caMEK5, or caMEK1+caMEK5 increased vimentin expression and reduced the ability of 
trametinib to decrease vimentin expression (Figure 4.14). In spheroid culture, trametinib, 
but not XMD8-92, treatment reduced expression of vimentin at 96 hours, which was 
rescued by transfection of caMEK1, caMEK5, or caMEK1+caMEK5 (Figure 4.14).  
Spheroid viability was assessed after 7 days of treatment with inhibitors or caMEKs 
(Figure 4.15). There was no baseline difference in spheroid viability after treatment with 
caMEK1, caMEK5, or caMEK1+caMEK5 groups. This may indicate that the spheroid-




increased. XMD8-92 significantly decreased spheroid viability at 1 and 10 µM 
concentrations. As expected, the reduction in spheroid viability at 1µM XMD8-92 
concentration was rescued by co-treatment with caMEK5 or caMEK1+caMEK5. This 
effect of caMEK5 or caMEK1+caMEK5 transfection was reversed in the presence of a 
higher XMD8-92 concentration (10µM). While trametinib significantly decreased spheroid 
viability at 0.1µM concentration, this decrease in viability was not reversed in the presence 
of caMEK1, caMEK5, or caMEK1+caMEK5 (Figure 4.15). Pictures of vimentin-expressing 
spheroids at day 0, day 7, and evidence of lentivirus infection measured by examining 






Figure 4.14. MEK1 and/or MEK5 activation reduces the ability of XMD8-92 or trametinib to decrease vimentin 
expression in MDA-MB-231 VIM RFP cells. (A) MDA-MB-231 VIM RFP cells were treated with constitutively active 
MEK1, MEK5, and MEK1+MEK5 in the presence of DMSO, XMD8-92, or trametinib for 72 hours. The cells were fixed and 
stained with Hoechst. Images of Vimentin-, GFP-, and Hoechst-expressing cells were captured under 40X magnification 
using EVOS microscope (n=3, most representative image shown). (B) MDA-MB-231 VIM RFP cells were treated with 
constitutively active MEK1, MEK5, and MEK1+MEK5 in the presence of DMSO, XMD8-92, or trametinib for 96 hours. 
Images of spheroids under transmitted light and RFP channel were captured under 4X magnification using EVOS 







Figure 4.15: MEK1 and/or MEK5 activation reduces the ability of XMD8-92 or 
trametinib to decrease spheroid viability in MDA-MB-231 VIM RFP cells. Spheroid 
viability was assessed after 7 days of treatment with the same groups. Data indicate ± 
SEM of experiments run in triplicate. ***p<0.001; ****p<0.0001 vs DMSO control group, 







Figure 4.16 Tra or XMD in the presence of constitutively active MEK1 and/or MEK5 affect spheroid viability in MDA-
MB-231 VIM RFP model. (A) Pictures of MDA-MB-231 VIM RFP spheroids before treatment. (B) Pictures of spheroids 




4.3.9 Effect of dual ERK1/2 and ERK5 pathway inhibition on cell viability and 
spheroid formation in breast cancer 
We wanted to further characterize the effect of pharmacological inhibition of the 
ERK1/2 and ERK5 pathways on cell viability and spheroid formation. Breast cancer cells 
were treated with increasing concentrations of XMD8-92 and trametinib (0.1, 0.3, 1, 3 and 
10 μM) alone and in combination for 72 hours (Figure 4.17). MTT assay was performed 
to evaluate cell viability. While trametinib and XMD8-92 alone decreased cell viability in 
MDA-MB-231 and TU-BcX-4IC cells, there was no synergy in combination groups. In BT-
549 cells, there was a reduction in cell viability after treatment with XMD8-92, but not 
trametinib. In TAMR MCF-7 cells, the combination of XMD8-92 and trametinib 
synergistically reduced cell viability. 
EMT is known to promote anchorage-independent growth.97, 112 We found that 
trametinib alone significantly decreased cell viability and/or spheroid viability in all breast 
cancer models and its effects were most pronounced in MDA-MB-231 cells (Figure 4.18)  
At the 10uM concentration, XMD8-92 decreased spheroid viability in MDA-MB-231 and 
TU-BcX-4lC cells, but not BT-549 or TAMR cells. The reduction in spheroid viability in 
response to trametinib was greater in MDA-MB-231 cells (~90%) compared to BT-549 
(~40%), TU-BcX-4IC (~35%), or TAMR-MCF-7 cells (~40%). These data suggest that 
while ERK1/2 and ERK5 inhibition is sufficient to target MDA-MB-231 and TAMR MCF-7 
cells, alternative pathways may be important to further reduce spheroid viability in BT-
549 and TU-BcX-4IC cells. The combination of Tra+XMD at the 0.1 and 1uM 
concentrations, synergistically inhibited spheroid viability in TAMR MCF-7 cells, but not 




inhibition is a relevant strategy to target tamoxifen-resistant breast cancer cells.  
Additional alternative pathways that may mediate survival in TNBC cells will be discussed 
in chapter 5.
 
Figure 4.17: Effect of XMD8-92 and trametinib alone and in combination on breast cancer 
cell viability. Effect of simultaneous treatment with XMD8-92 and trametinib was evaluated 
compared to XMD and trametinib alone. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 vs 
trametinib; ##p<0.01; ###p<0.001; ####p<0.0001 vs XMD8-92 as determined by two-way 

















Figure 4.18. Effect of ERK1/2 and ERK5 inhibition alone and together on spheroid viability in diverse breast cancer subtypes. 
The cells were treated with increasing concentrations of XMD8-92 and/or trametinib for 7 days. Pictures of spheroids were obtained 
before treatment and 7 days after treatment (4X magnification) (A) MDA-MB-231, (B) BT-549, and (C) TU-BcX-4IC, and (D) TAMR 
MCF-7 cells. Data indicate ± SEM of experiments run in triplicate *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 vs DMSO control group, 






4.4 Discussion  
Mesenchymal cancer cells are migratory and invasive, leading to metastases. 
There are currently no effective treatments for metastasis. Interestingly, activation of the 
ERK1/2 and ERK5 signaling pathways leads to an epithelial to mesenchymal transition 
(EMT) and poor patient survival in several cancers, including TNBC and endocrine-
resistant breast cancers.16, 23, 30, 102-104, 115-117 Genomics data from our research indicate 
that MAPK3 (ERK2) and MAPK7 (ERK5) gene expression significantly correlated with the 
mesenchymal markers VIM or ZEB1, but not with the epithelial marker CDH1 (Figure 4.1A 
and C). MAPK1 (ERK1) positively correlated with mesenchymal markers VIM and ZEB1 
and epithelial marker CDH1 (E-cadherin), indicating that MAPK1 may mediate an 
intermediate epithelial/mesenchymal state where both epithelial and mesenchymal 
markers are co-expressed (Figure 4.1B). These data support a role for ERK1/2 and ERK5 
signaling in EMT in TNBC. However, the relative roles of these pathways in inducing MET, 
a reversal of the EMT, in these cancers is unknown. Understanding of EMT and response 
to therapy is further complicated due to crosstalk between the ERK1/2 and ERK5 
pathways and different functions of ERK5 in the nucleus versus the cytosol. To our 
knowledge, this is the first study to examine the independent and overlapping roles of the 
ERK1/2 and ERK5 signaling cascades on MET, nuclear localization of ERK5, cell 
migration, proliferation, and spheroid formation in TNBC and TAMR breast cancer. 
In the current study, trametinib, a clinically relevant MEK1/2 inhibitor, and XMD8-
92, an ERK5 inhibitor, induced a MET in MDA-MB-231 TNBC cells as shown by 






expression of ZEB1 (Figure 4.3A). In MDA-MB-231, BT-549, TU-BcX-4IC, and TAMR 
MCF-7 cells, treatment with trametinib resulted in an epithelial-like morphology (Figure 
4.3B-D). However, the morphological changes induced by trametinib in BT-549 cells were 
less pronounced than those in MDA-MB-231 cells. This could be due to inhibition of both 
ERK1/2 and ERK5 pathways, a subsequent increase in E-cadherin, and decrease in 
ZEB1 expression by trametinib in MDA-MB-231 cells, but not in BT-549 cells. XMD8-92 
treatment only induced an epithelial morphology MDA-MB-231 cells. Interestingly, the 
morphological changes induced by trametinib in the MDA-MB-231 cells were more 
pronounced than those induced by XMD8-92. Again, this may be because trametinib 
inhibited both ERK pathways and altered expression of cell markers in favor of an 
epithelial phenotype (increased E-cadherin; decreased ZEB1), while XMD8-92 only 
inhibited the ERK5 pathway and reduced only ZEB1 expression in MDA-MB-231 cells. 
Overall, these data suggest that inhibition of ERK1/2 or ERK5 activity is sufficient to 
induce an MET in MDA-MB-231 cells, while inhibition of both ERK1/2 and ERK5 pathways 
may be necessary to induce a full MET. Conversely, in BT-549, TU-BcX-4IC, and TAMR 
MCF-7 cells, inhibition of the ERK1/2 pathway may be sufficient to induce an MET. 
Additionally, as trametinib consistently increased E-cadherin in TNBC and TAMR breast 
cancer models, E-cadherin may be used as a potential biomarker to predict MET induced 
by trametinib treatment in metastatic cancers.  
Consistent with the effect on MET, trametinib decreased cell migration in TNBC 
and TAMR MCF-7 cells, suggesting that ERK1/2 inhibition is sufficient to decrease cell 






in MDA-MB-231 cells. Again, these data are consistent with the induction of MET 
following XMD8-92 treatment in MDA-MB-231 cells and suggest that ERK5 pathway 
inhibition is also sufficient to decrease cell migration in MDA-MB-231 cells.  
ERK1/2 and ERK5 activation are known to mediate cell proliferation by mediating 
G1-S transition during the cell cycle via distinct effects on cyclinD1 expression and 
activation.118 Trametinib decreased cell proliferation by 80% in TAMR MCF-7 cells. 
However, in MDA-MB-231 cells, trametinib only decreased cell proliferation by ~50%. 
These findings suggest that alternative pathways may mediate cell proliferation in these 
cells. The effect of XMD8-92 on cell proliferation was evident only at the highest dose (10 
μM) in MDA-MB-231 and TAMR MCF-7 cells. We have previously shown that effects of 
a high XMD8-92 dose could be recapitulated by the addition of AX15836 (ERK5 inhibitor) 
and CPI203 (BRD4 inhibitor).37 Therefore, at high doses, in addition to ERK5 inhibition, 
XMD8-92 may have off-target effects, including inhibition of bromodomain (BRD)4.119 
Trametinib or XMD8-92 did not decrease cell proliferation in BT-549 cells, which may 
indicate that alternative pathways mediate cell proliferation in these cells. XMD8-92 
significantly decreased cell proliferation at 10 μM concentration, while trametinib did not 
decrease cell proliferation in TU-BcX-4IC cells. As indicated above, BT-549 cells are 
PTEN mutant cells and may rely more on the AKT pathway for survival and proliferation. 
Additionally, together with the data on cell migration, these data suggest that migration 
and proliferation may be controlled by distinct mechanism in TNBC cells.   
We observed that MDA-MB-231 cells were the most responsive to the effects of 






led us to characterize differences in cellular signaling between the two TNBC models.  To 
explore these putative differences in the MAPK signaling pathways, we first examined the 
effects of trametinib and XMD8-92 on nuclear localization of ERK5. Our is the first study 
to examine nuclear localization of ERK5 in TNBC.  
We found that the ERK5 inhibitor did not decrease nuclear ERK5 activation or total 
expression. This observation is consistent with a recent study, which has shown that 
ERK5 inhibitors that target the kinase domain were shown to activate the transcriptional 
activation domain (TAD) of ERK5, resulting in the nuclear localization and increased 
transcriptional activity of ERK5.120 This may explain why our data with respect to the effect 
of ERK5 inhibition on E-cadherin conflicts with studies that have shown that inhibition of 
ERK5 via knockdown or knockout enhances E-cadherin expression in several cancer 
models.121-122 Since trametinib decreased nuclear ERK5, ERK1/2 activation may be a 
putative mechanism for the translocation of ERK5 into the nucleus in MDA-MB-231 cells. 
ERK1/2 has been shown previously to promote ERK5 translocation to the nucleus in 
response to growth factor stimulation.59 However, constitutively active RAF may be 
responsible for constitutive ERK1/2 activation and subsequent translocation of ERK5 in 
the nucleus of MDA-MB-231 cells under unstimulated condition. We are currently 
investigating mechanisms for ERK5 nuclear translocation in BT-549 cells. 
To further explore hypothesis that inhibition of both the ERK1/2 and ERK5 
pathways are necessary to induce the MET in TNBC, MDA-MB-231 and BT-549 cells 
were infected with dominant negative (dn) and constitutive active (ca) MEK1 and/or 






the morphological transitions were more pronounced when both pathways were activated 
or inhibited in MDA-MB-231 and BT-549 cells. This was supported by decrease in ZEB1 
expression in MDA-MB-231 cells following dnMEK1 and/or dnMEK5 infection and 
increase in ZEB1 expression in BT-549 cells following caMEK1 and/or caMEK5 infection 
(Figure 4.12). It is possible that ZEB1 expression is maximum in MDA-MB-231 cells and 
could not be induced further. Therefore, the more pronounced mesenchymal morphology 
following caMEK5 and caMEK1+caMEK5 infection may be a result of increase in vimentin 
expression (Figure 4.14) and/or ERK5 activation (Figure 4.10B) and its association with 
the actin cytoskeleton as previously described.108 Moreover, ERK5 activation increased 
more significantly in caMEK1 + caMEK5 group vs GFP than in the caMEK5 group vs GFP 
(Figure 4.10B), indicating that ERK5 may be activated by both MEK1 and MEK5 signaling. 
This observation supports the data that show that trametinib, a known MEK1/2 inhibitor, 
decreased ERK5 activation in MDA-MB-231 cells. We speculate that the effect of 
trametinib on ERK5 inhibition was mediated via MEK1/2 inhibition and not by direct 
binding of trametinib to MEK5 or ERK5. Since ERK1/2 and ERK5 share 50% sequence 
homology at the N-terminal domain, it is possible that MEK1/2 may phosphorylate ERK5 
by direct binding. It is also possible that ERK1/2 may phosphorylate ERK5 at its C-
terminal by direct interaction, as reported previously.59 These data further support the 
conclusion that inhibition or activation of both pathways is necessary for the MET or EMT, 
respectively. These data, together with the effect of trametinib and XMD8-92 on 
morphology, suggest that inhibition of both the ERK1/2 and ERK5 pathways is necessary 






The trametinib-mediated decrease in ZEB1 expression was partially reversed in 
MDA-MB-231 cells transfection with caMEK5. These data suggest that trametinib 
mediates its effect on MET in MDA-MB-231 cells, at least in part, via ERK5 inhibition and, 
most likely, via dual ERK1/2 and ERK5 inhibition. However, the trametinib-mediated 
increase in E-cadherin expression was not decreased by caMEK5, which may indicate 
that trametinib induces E-cadherin expression via ERK1/2 inhibition alone in these TNBC 
cells. This observation further supports the data that suggest there is no change in E-
cadherin expression following XMD8-92 treatment in MDA-MB-231 cells.  
While trametinib caused an overall decrease in ZEB1 expression in BT-549 cells, 
transfection with caMEK5 did not decrease its ability to induce MET as determined by 
examining cell morphology, E-cadherin, expression, and ZEB1 expression. This further 
supports our data that suggest that ERK1/2 inhibition, but not ERK5 inhibition, induces 
MET in BT-549 cells. We also observed that there was an overall reduction in ZEB1 
expression in cells with an epithelial morphology following treatment with trametinib in 
both the TNBC cell lines and there was no cell population that had a complete loss of 
ZEB1. Such fine-tuning could be advantageous to avoid catastrophic side effects on 
healthy mesenchymal cells in the body, which depend on ZEB1 for their normal function. 
The effect of ERK1/2 and ERK5 pathway inhibition or activation on vimentin 
expression were examined in 2D and spheroid cultures of MDA-MB-231 cells. Trametinib 
moderately decreased vimentin expression in MDA-MB-231 VIM RFP cells in 2D culture 
(Figure 4.14A), but completely inhibited vimentin expression in spheroid culture (Figure 






mesenchymal and anoikis-resistant cells. Moreover, trametinib-mediated decrease in 
spheroid viability was not rescued by caMEK1, caMEK5, and caMEK1+caMEK5 groups 
at 7 day (Figure 4.15). This indicates that the reduction in vimentin expression in 
spheroids was not due to a decrease in spheroid viability. Since the reduction of vimentin 
by trametinib was partially reversed by co-treatment with constitutively active MEK1 
and/or MEK5, trametinib-mediated decrease in vimentin may be due to inhibition of both 
ERK1/2 and ERK5 pathways in MDA-MB-231 cells. XMD8-92 significantly decreased the 
spheroid viability at 1µM concentration, which was rescued by caMEK5 and 
caMEK1+caMEK5 transfection indicating that ERK5 has a crucial role in regulating the 
survival of anoikis-resistant spheroids (Figure 4.15). Dysregulation of anoikis, a type of 
programmed cell death that occurs in cells when they detach from a cellular matrix, is an 
important step in tumor metastases. Together, these data suggest that ERK1/2 activation 
has a greater role in regulating the EMT in spheroids, while ERK5 activation regulates the 
survival of these anoikis-resistant spheroids. 
As previously described, some single-agent inhibitors of MAPK pathway(s) led to 
an intermediate E/M state, which may be a predictor of metastases and poor prognosis. 
Therefore, combination strategy for MAPK inhibitors needs to be developed. We 
examined the effect of dual ERK1/2 and ERK5 pathway inhibition on spheroid viability, 
an assay representative of EMT. MAPK gene alterations are common in endocrine-
resistant breast cancer.123 This explains why Tra and XMD combination produced greater 
inhibition of spheroid and cell viability compared to either drug alone in TAMR MCF-7 






ERK5 pathways in mediating EMT and MET, cell migration, proliferation, and spheroid 
formation in TNBC and TAMR breast cancer. Since crosstalk may exist between the 
MAPK and PI3K or epigenetic pathways, in the next chapter, we will discuss some 





















Chapter 5: Effect of Compound 1 (SC-1-151) alone and in combination with 
epigenetic inhibitors, CDK4/6 inhibitor Palbociclib, or AKT inhibitor ipatasertib on 
cell viability, proliferation, or spheroid formation in breast cancer 
5.1 Introduction 
The use of MEK1/2 inhibitors as cancer therapeutics has been clinically beneficial 
for treatment of previously incurable cancers, such as melanomas. However, the 
therapeutic use of MEK1/2 inhibitors is limited due to dose-dependent side effects and 
drug resistance. Therefore, several components, including activation mechanisms, 
kinase-substrate relationships, feedback mechanisms, and crosstalk with parallel 
pathways, need to be examined.   
We have shown that the novel dual MEK1/2 and MEK5 inhibitor, compound 1 (SC-
1-151; compound 1 will be referred to as SC-1-151 from here on) decreases cell 
proliferation, migration, and spheroid formation in the previous chapter. However, 
sustained inhibition of the MAPK pathway can result in the loss of negative feedback-
mediated inactivation loops and paradoxical activation of ERK.124 This could be mediated 
via a decreased expression of tumor suppressor dual specificity phosphatase (DUSP) 6, 
which is transcriptionally regulated by members of the Erythroblast Transformation 
Specific (ETS) family of transcription factors.125 Reactivation of RNA polymerase-II-
mediated parallel survival pathway transcription factors, such as ETS1, ETS2, and 
bromodomain 4 (BRD4), have been shown to compensate for the inhibition of the MAPK 
pathway, limiting the standalone targeting of MAPKs (Figure 5.1). In fact, BRD4 is known 






combination of MAPK inhibitors with transcription factor-targeted small molecule 
inhibitors, such as JQ-1 (pan-BRD inhibitor), is a relevant strategy for the treatment of 
breast cancer tumorigenesis. Histone deacetylases (HDACs) are another class of 
epigenetic regulators that are also known to mediate resistance to MAPK inhibitors in 
melanoma and prostate cancer.127-128 Therefore, we hypothesized that SC-1-151+LBH-
589 (HDAC inhibitor) will synergize to reduce cell viability in triple-negative and TAMR 
breast cancers. 
 
Figure 5.1: Negative feedback regulation of RAS/MAPK pathway.129 
 Dysregulation of the cell cycle often accompanies the dysregulation of the MAPK 
pathways, either as a direct consequence of aberrant MAPK activation (or vice versa) or 
as parallel pathways that promote tumorigenesis (Figure 5.2).20, 130 Cyclin-dependent 
kinase 4/6 (CDK4/6) phosphorylates retinoblastoma (Rb) and promotes entry into the cell 






inhibitors block Rb phosphorylation and lead to cell cycle arrest. Palbociclib, an oral and 
selective CDK4/6 inhibitor, is FDA approved for use in the first- and second-line settings 
for metastatic hormone-receptor positive breast cancer. Moreover, CDK4/6 inhibitors in 
combination with MAPK inhibitors decrease cell proliferation in melanoma, head and neck 
cancer, and colorectal cancer.131 However, the effect of CDK4/6 inhibitors in combination 
with MAPK inhibitors at low concentration in tamoxifen-resistant breast cancer remains 
unknown. As crosstalk between the ERK and AKT signaling pathways has been noted in 
TNBC,37 the AKT pathway may lead to reduced efficacy of MAPK inhibitors in TNBC. 
Therefore, the effect of MAPK pathway inhibition in combination with AKT inhibition was 
evaluated on spheroid viability in TNBC and TAMR MCF-7 cells. 
In this chapter, we explore three strategies to improve the efficacy SC-1-151. First, 
we examine the effect of cotreatment with inhibitors of MAPK signaling and 
bromodomains or HDAC on cell viability in TNBC and TAMR cells using SC-1-151 in 
combination with JQ-1. Next, we evaluate the effect of SC-1-151 in combination with 
palbociclib on cell proliferation in TAMR breast cancer cells. Finally, SC-1-151 or the 
MEK5 inhibitor SC-1-181 was used in combination with the AKT inhibitor ipatasertib to 
evaluate the effect of combination on spheroid viability. Overall, these strategies may help 







Figure 5.2: ERK5, ERK1/2, and CDK4/6 pathways and the cell cycle. ERK1/2 and 
ERK5 pathways may regulate the cell cycle and proliferation via CD1 and CDK4/6.  
5.2 Hypothesis 
SC-1-151 and epigenetic, CDK4/6, or AKT inhibitors will produce a synergistic decrease 
in cell viability in triple-negative and tamoxifen-resistant breast cancer cells. 
5.3 Results 







Figure 5.3: Effect of SC-1-151 on breast cancer cell viability.  Cells were treated with 
SC-1-151 at increasing concentrations for 72 hours. MTT assay was performed to assess 
cell viability.  
TNBC and TAMR breast cancer cell lines were treated with SC-1-151 at increasing 
concentrations (0.01, 0.03, 0.1, 0.3, 1, 3, 10 uM) for 72 hours. MTT assay was performed 
to assess cell viability. SC-1-151 decreased cell viability at 0.01 – 10uM concentrations 
in MDA-MB-231 cells, but not in BT-549 cells or in ERK5 knockout (KO) MDA-MB-231 
cells. SC-1-151 was equally effective in reducing cell viability in wildtype and tamoxifen-
resistant MCF-7 cells (Figure 5.3).  
5.3.2 SC-1-151 synergistically inhibits cell viability in combination with JQ-1 in 
breast cancer 
Since sustained MAPK inhibition may result in a loss of feedback mediated via 
DUSP6, it is important to investigate the effect of MEK inhibitors in combination with 
alternative therapies.  Since alternative pathways, including BRD4 or HDAC signaling, 




























could promote cell survival in the absence of MEK1/2 signaling, we combined SC-1-151 
with bromodomain inhibitor JQ-1 or HDAC inhibitor LBH589.  SC-1-151 and JQ-1 were 
found to synergistically decrease cell viability in TNBC and TAMR cells at low 
concentrations. There was a greater that 50% reduction in cell viability after treatment of 
TNBC cells with 0.3 uM concentration of each inhibitor and TAMR cells with 0.1 uM of 
each inhibitor as indicated by the fraction affected (Figure 5.4, Table 5.1).     
The crosstalk between RAS and PI3K pathways is well-defined in cancer.132 
Interestingly, we have noted an increase in AKT activation following treatment with SC-
1-151. Others have reported that JQ-1 decreases AKT activation in endometrial cancer 
via upregulation of PTEN.133 Therefore, to gain mechanistic insights behind the observed 
synergy between SC-1-151 and JQ-1, ERK1/2 and AKT activation was examined after 5 
days of treatment with SC-1-151 or JQ-1 alone and in combination.  SC-1-151, but not 
JQ-1, inhibited ERK1/2 phosphorylation, however, the combination of SC-1-151 and JQ-
1 produced a greater inhibition of ERK1/2 phosphorylation than SC-1-151 alone. A 
compensatory increase in AKT phosphorylation was noted following SC-1-151 treatment. 
While JQ-1 did not decrease AKT activity alone, it inhibited the increase in AKT activation 









Figure 5.4: SC-1-151 + JQ-1 combination synergistically decreases cell viability in 
diverse breast cancer subtypes. (A) MDA-MB-231, (B) BT-549, (C) MCF-7 TAMR cells 
were treated with drugs alone and in combination for 72 hours. Cell viability was 















Table 5.1: Effect of SC-1-151 and JQ-1 combination on fraction affected and 
combination index. The fraction affected was calculated and synergy was determined 
by Chou-Talalay Method using CompuSyn Software. 
 




Figure 5.5: JQ-1 decreases AKT activation induced by SC-1-151 treatment in MDA-
MB-231 cells. MDA-MB-231 cells were treated with 1 μM SC-1-151 and 300 nM JQ-1 
alone and in combination for 5 days. ERK1/2 and AKT activation was examined by 
western blotting. Data were analyzed by One-way ANOVA with Bonferroni post-hoc 







5.3.4 SC-1-151 and LBH-589 cotreatment does not synergistically reduce cell 
viability in TNBC and TAMR MCF-7 cells.  
 
 MDA-MB-231, BT-549, and TAMR MCF-7 cells were treated with increasing 
concentrations of SC-1-151, LBH-589, and 1:1 combination of the two drugs for 72 hours. 
Our data suggest that LBH-589 or SC-1-151 treatment alone inhibited cell viability in 
breast cancer cell lines. SC-1-151+LBH-589 cotreatment did not produce a synergistic 
reduction in cell viability in TNBC cells (Figure 5.6). The lack of synergy may be due to a 
maximal decrease in cell viability following LBH-589 treatment alone.  
We also examined ERK1/2 and AKT activation after treatment with 100nM LBH-
589 or 1 μM SC-1-151 alone and in combination. LBH-589 produced a compensatory 
increase in ERK1/2 activation. This increase in ERK1/2 activation was inhibited by SC-1-
151. Both SC-1-151 and LBH-589 treatment alone produced a 10-fold increase in AKT 










Figure 5.6: SC-1-151 + LBH589 modestly synergize to decrease cell viability in BT-
549 cells. (A) MDA-MB-231, (B) BT-549, (C) MCF-7 TAMR cells were treated with drugs 








Figure 5.7: SC-1-151 and LBH-589 activate AKT in MDA-MB-231 cells. MDA-MB-231 
cells were treated with SC-1-151 and LBH-589 alone and together to examine kinase 
activation after 5 days of treatment. 
 
5.3.5 Effect of SC-1-151+Palbociclib on cell proliferation in TAMR MCF-7 cells.  
 Recent studies have shown that MEK inhibition is important for enhanced efficacy 
of CDK4/6 inhibitors in various cancer models.131 TAMR MCF-7 cells were treated with 
SC-1-151 and palbociclib alone and in combination at 0.1 or 1 µM concentration. 
Palbociclib significantly decreased cell proliferation at 0.1 and 1 µM concentrations, while 
SC-1-151 decreased cell proliferation only at the 1 µM concentration. In the combination 







Figure 5.8: Effect of SC-1-151 in combination with Palbociclib on cell proliferation 






 Since the reduction in cell proliferation in 1:1 SC-1-151:Palb combination groups 
was dominated by palb, we examined the effect of a larger ratio of SC-1-151 to Palbociclib  
(10:1 combination ratio). SC-1-151 (1uM) and Palbociclib (0.1uM) synergistically 
decreased cell proliferation in wildtype MCF-7 cells (Figure 5.9A); however, the reduction 
in cell proliferation in TAMR MCF-7 cells was mainly mediated by SC-1-151. While 
Palbociclib alone significantly decreased cell proliferation, there was no further reduction 







Figure 5.9: SC-1-151 and Palbociclib synergistically decrease cell proliferation in 
(A) WT-MCF-7 cells but not in (B) TAMR-MCF-7 cells.  
 
5.3.6 Inhibition of MEK1/2, MEK5, and PI3K pathways decreases nuclear ERK5 
expression or activation and decreases spheroid viability in breast cancer cells. 
 
Treatment with the AKT inhibitor ipatasertib alone, did not decrease spheroid 
viability in MDA-MB-231 and TAMR MCF-7 cells. However, the effect of ipatasertib on 
cell viability was potentiated by MEK inhibitors in these cells (Figure 5.10 A, C). Ipatasertib 
alone decreased spheroid formation in BT-549 and TU-BcX-4IC cells and there was a 
synergistic effect when these cells were treated with ipatasertib in combination with the 























Figure 5.10: Effect of SC-1-151 or SC-1-181 in combination with ipatasertib on spheroid viability in diverse breast 
cancer subtypes. Effect of SC-1-151 (dual MEK1/2 and MEK5 inhibitor) or SC-1-181 (MEK5 inhibitor) alone and in 
combination with ipatasertib was evaluated on spheroid viability in (E) MDA-MB-231, (F) BT-549, (G) TU-BcX-4IC and (H) 
TAMR MCF-7 cells. Spheroid viability was assessed on day 7 after treatment. Data indicate ± SEM of experiments run in 
triplicate *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 vs DMSO control group, ##p<0.01; ###p<0.001; ####p<0.0001 vs 





 Our findings suggest that alternative mechanisms may underlie the activation and 
nuclear translocation of ERK5 in BT-549 cells because treatment with ERK5 inhibitor 
XMD8-92 or MEK1/2 inhibitor trametinib did not decrease nuclear ERK5 activation in BT-
549 cells. This may also explain why trametinib only induced a partial MET and XMD did 
not induce a MET in BT-549 cells. We hypothesized that nuclear ERK5 may be 
responsible for increasing the transcription of genes involved in EMT and spheroid 
formation. To understand the differences in response to Ipat+181 or Ipat+151 treatment 
in different breast cancer subtypes, MDA-MB-231 (responsive to MEK1/2 and MEK5 
inhibition) and BT-549 cells (responsive to MEK1/2, MEK5, and AKT inhibition) were 
treated with ipatasertib alone and in combination with SC-1-181 or SC-1-151 for 72 hours 
and nuclear extracts were collected to examine ERK5 activity and expression of a MEF2 
family member MEF2C, a downstream target of ERK5 signaling. MEF2C levels in the 
nucleus are representative of ERK5 activity.134 
In MDA-MB-231 cells, SC-1-151, like trametinib (Chapter 4), decreased nuclear 
ERK5. SC-1-151 and Ipat+SC-1-151 combination groups produced a maximum decrease 
in nuclear ERK5 and MEF2C expression. SC-1-181 or Ipatasertib alone or in combination 
did not decrease nuclear ERK5 activation, expression. Ipat+SC-1-151 group produced a 
maximum decrease in MEF2C expression (Figure 5.11A).  In BT-549 cells, ipatasertib 
modestly decreased ERK5 activation and SC-1-181 modestly decreased MEF2C 
expression. Surprisingly, ipatasertib in combination with SC-1-181 or SC-1-151 produced 






Figure 5.11: Inhibition of MAPK and PI3K pathways decreases nuclear ERK5 and 
MEF2C in TNBC cells. (A) MDA-MB-231 (B) BT-549 cells were treated with AKT inhibitor 
ipatasertib alone and in combination with SC-1-181 of SC-1-151 for 72 hours. Nuclear 
extracts were prepared as per the standard protocol.  
 
5.4 Discussion: 
In this chapter, we further characterized the effects of SC1-151 on TNBC and 
TAMR viability, examined the effects of SC-1-151 alone and in combination with a BRD4, 
HDAC, or cell cycle inhibitor on breast cancer cell viability and proliferation, and examined 
the effect of the inhibitors on ERK1/2 and AKT pathway activation. SC-1-151 decreased 
cell viability in MDA-MB-231, TAMR MCF-7, and WT MCF-7 cells. In contrast, SC-1-151 
did not decrease cell viability in BT-549. MDA-MB-231 cells have a mutation in the RAF 
gene which leads to aberrant MEK activity. This may explain why these cells were more 
sensitive than BT-549 cells to the toxic effects of the dual ERK1/2 and ERK5 pathway 
inhibitor SC-1-151. The decrease in cell viability following SC-1-151 treatment in wildtype 
and TAMR MCF-7 cells suggests that tamoxifen-resistance does not affect the cell 
viability response to dual MEK1/2 and MEK5 inhibition. SC-1-151 did not inhibit cell 
viability in ERK5-KO MDA-MB-231 cell. This may indicate that inhibition either ERK1/2 or 
ERK5 pathway may be sufficient to decrease cell viability in MDA-MB-231 cells and 




In the current study, inhibition of MEK1/2/5 and BRD4 with SC-1-151 and JQ-1, 
respectively, produces a synergistic effect on cell viability in TNBC and TAMR breast 
cancer cells. This synergy may be a result of inhibition of shared downstream targets. 
ETS1/2 is an important downstream target of the ERK1/2 pathway. ETS1/2-mediated 
gene transcription is also mediated by bromodomain 4 (Figure 5.12). Moreover, we found 
that a compensatory increase in AKT activation by SC-1-151 was inhibited by JQ-1, which 
may also explain the observed synergy. Although pharmacological inhibitors with dual 
ERK5/BRD4 activity are known to decrease cell proliferation in cancer, ours is the first 
study to report a synergistic effect on cell viability with inhibition of the ERK5 and BRD4 
pathways.119  
The effects of histone deacetylase inhibitors on tumor progression are being 
recently studied in metastatic breast cancers.135 Phase-III clinical trial with HDACi in 
breast cancer has shown promising results. HDAC inhibitors have been shown to 
synergize with MAPK inhibitors to inhibit cell viability and stemness in 
medulloblastomas.136 However, we did not observe synergy between MAPK and HDAC 
inhibitors in TNBC and TAMR breast cancer. The increase in AKT activation by SC-1-151 
(dual MEK1/2 and MEK5 inhibitor) and LBH-589 may be responsible for lack of synergistic 
response in the combination group. LBH-589 (HDAC inhibitor) alone may have decreased 
cell viability to its maximum. In future, more combination ratios will be utilized to evaluate 
the effect on cell viability as well as other functional assays representative of EMT.  MDA-
MB-231 cells have a mutation in the RAF gene which leads to aberrant MAPK activity. 
This may explain why these cells were more sensitive to the toxic effects of the dual 




highlights the relevance of targeting MAPK pathway in combination with BET or HDAC 
inhibitors to target cell viability and proliferation in breast cancer. 
 
Figure 5.12: Coregulation of ETS1/2-mediated response by MEK1/2 and 
bromodomain pathways.129 
  
Cyclin-dependent kinases play a critical role in regulating the cell cycle and are 
relevant targets in cancer. Activation of cyclinD1 levels by upstream mitogenic factors and 
activation of RAS-RAF-MEK-ERK can promote cellular progression to the S phase and 
compensate for inhibition of the cell cycle by CDK4/6 inhibitors.130 To explore a possible 
synergistic effect of MAPK and cell cycle inhibition, we examined proliferation in WT and 
TAMR MCF-7 cells following treatment with SC-1-151 or Palbociclib, the CDK4/6 inhibitor, 
alone and in combination. In the SC-1-151 and palbociclib combination, the reduction in 
cell proliferation was mediated by either palbociclib in 1:1 combination or SC-1-151 in 
10:1 combination group. Future studies will be performed to utilize more combination 
ratios and to examine synergy.  
We found that dual ERK1/2 and ERK5 inhibition was sufficient to inhibit spheroid 
viability in MDA-MB-231 and TAMR MCF-7 cells but further inhibition of AKT was 




difference may be because SC-1-151, inhibits both ERK1/2 and ERK5 activation by EGF 
in MDA-MB-231 and TAMR MCF-7 cells, but only inhibits the ERK1/2 activation in BT-
549 cells. We found that dual ERK1/2 and ERK5 inhibition was sufficient to decrease 
spheroid formation in MDA-MB-231 and TAMR-MCF-7 cells whereas additional inhibition 
of AKT was necessary further inhibit spheroid formation in BT-549 and TU-BcX-4IC cells. 
 As discussed in the previous chapter, trametinib, a MEK1/2 inhibitor or XMD8-92, 
an ERK5 inhibitor did not reduce nuclear ERK5 in BT-549 cells meaning alternative 
pathways may regulate ERK5 nuclear localization in BT-549 cells. Since crosstalk 
between ERK5 and AKT pathways has been noted and BT-549 cells have a PTEN 
mutation, we examined whether inhibition of AKT would reduce nuclear ERK5 activity. 
ERK5 activation and MEF2C expression were examined after treating MDA-MB-231 and 
BT-549 cells with ipatasertib alone and in combination with SC-1-181 or SC-1-151. 
Overall, our data suggest that MEK1/2, MEK5, and AKT pathways play an important role 
in regulating nuclear ERK5 activity. Decrease in nuclear ERK5 activity may be one of the 









Chapter 6: Effect of MAPK or PI3K pathway inhibition on low-dose 
chemotherapeutic sensitivity in triple-negative breast cancer 
6.1 Introduction 
Doxorubicin, paclitaxel, and carboplatin are the chemotherapeutic drugs that 
remain the mainstay treatment for TNBC patients.137 Unfortunately, TNBCs become 
resistant to most chemotherapeutic drugs. Drug resistance and off-target toxicity are 
major problems associated with administration of high doses of chemotherapeutic agents 
in the clinic. Inherent and acquired mechanisms of drug resistance include dependence 
of tumors on alternative/novel mutations, increase in drug efflux transporters, and 
compensatory activation of kinase pathways, which can prolong the survival of cancer 
cells.  
ERK5 overexpression is associated with poor overall survival in breast cancer 
patients after treatment with chemotherapeutic drugs (Figure 6.1).30 ERK5 inhibition is 
known to reverse doxorubicin resistance via p53 upregulation in lung and ovarian 
cancers.138 AKT activation is known to mediate resistance to doxorubicin by 
downregulated PTEN expression in ER-positive breast cancer.139 Moreover, 
downregulation of ETS-1, a target of ERK1/2  was found to enhance cisplatin and 
doxorubicin toxicity in breast cancer.18  In ovarian cancer, ERK1/2 activation following 
cisplatin treatment has been shown to mediate resistance to cisplatin.140 Moreover, 
ERK1/2 and AKT pathways are known to mediate chemoresistance in cancer via 
upregulation of multi-drug transporter proteins.141-142 The goal of this research is to 




viability in combination with known MAPK pathway inhibitors XMD8-92, trametinib, and 
ipatasertib.  
 
 Figure 6.1: Poor overall survival after systemic treatment is associated with MEK5-





Chemotherapeutic drugs will enhance sensitivity of MAPK or PI3K pathway inhibitors at 
low doses in triple-negative breast cancer cells. 
6.3 Results 
6.3.1 Effect of chemotherapeutic drugs doxorubicin, paclitaxel, and carboplatin on 
cell viability in TNBC  
Concentration-response studies revealed differential responses of MDA-MB-231 
and BT-549 cells to different chemotherapeutic drugs (Figure 6.2). These studies were 
performed to identify low doses at which the chemotherapeutic drug produced no effect 
on cell viability. Cells are resistant to the toxic effects of the drugs at low doses and the 
goal of our research is to examine whether combination of low-dose kinase inhibitors with 





Figure 6.2: Cell viability response to doxorubicin, paclitaxel, and carboplatin in (A-
C) MDA-MB-231 and (D-F) BT-549 cells.  
 
Drug MDA-MB-231 BT-549 
Doxorubicin 100 nM 10 nM 
Paclitaxel 100 pM 100 pM 
Carboplatin 100 μM 10 μM 
Table 6.1: Concentration at which the drug alone did not decrease cell viability. 
MTT-assay was performed to examine the effect of increasing concentrations of 
doxorubicin, paclitaxel, and carboplatin in MDA-MB-231 and BT-549 cells. The maximum 
concentration to produce no significant reduction in cell viability was selected and these 
concentrations are summarized in the table. 
 
6.3.2 Cotreatment with low doses of kinase inhibitors and doxorubicin produces 
toxicity in both MDA-MB-231 and BT-549 cells. 
MDA-MB-231 and BT-549 cells were treated with increasing concentrations (0.01, 
0.03, 0.1, 0.3, and 1 μM) of the ERK5 inhibitor XMD8-92, the MEK1/2 inhibitor trametinib, 
and the AKT inhibitor ipatasertib. These doses of inhibitors did not decrease TNBC cell 
viability (Figure 6.3). DMSO or low-dose doxorubicin were added to TNBCs treated with 
the various doses of kinase inhibitors (Table 6.1). After 72 hours of treatment, MTT assay 
was performed to assess cell viability. Cotreatment with low dose of doxorubicin 
sensitized MDA-MB-231 and BT-549 cells to low doses of XMD8-92 (Figure 6.3 A, D). 
Trametinib and ipatasertib alone decreased MDA-MB-231 cell viability even at low doses. 
Doxorubicin did not enhance the toxicity of either kinase inhibitor (Figure 6.3C). In BT-




own. However, in combination with low dose doxorubicin both trametinib and ipatasertib 
significantly decreased in cell viability in BT-549 cells (Figure 6.3F).  
 
Figure 6.3: Effect of doxorubicin in combination with kinase inhibitors at 72 hours. 
Data represent the ± SEM of three independent experiments as a percentage of untreated 
DMSO control group. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 combination vs. drug 
alone determined by two-way ANOVA with the Bonferroni post hoc test. 
 
6.3.3 Single pathway kinase inhibitors do not enhance paclitaxel or carboplatin 
sensitivity in TNBC cells: 
 Similar as described above, TNBC cells were treated with paclitaxel or carboplatin 
in combination with kinase inhibitors. With the exception of potentiation at low doses of 
XMD8-92 in MD-MB-231 cells, cotreatment with paclitaxel or carboplatin and the kinase 
inhibitors did not significantly decrease cell viability (Figure 6.4 and 6.5). Interestingly, 
there was an antagonistic interaction between trametinib and paclitaxel or carboplatin 
because combination with paclitaxel or carboplatin reduced the ability of trametinib to 





Figure 6.4: Effect of paclitaxel in combination with kinase inhibitors at 72 hours. 
Data represent the ± SEM of three independent experiments as a percentage of untreated 
DMSO control group. *p<0.05; **p<0.01 combination vs. drug alone determined by two-
way ANOVA with the Bonferroni post hoc test. 
 
 
Figure 6.5: Effect of carboplatin in combination with kinase inhibitors at 72 hours. 




DMSO control group. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 combination vs. drug 
alone determined by two-way ANOVA with the Bonferroni post hoc test. 
  
 The drug efflux transporters, MDR1 and MRP1, are major drivers of 
chemotherapeutic resistance in several cancers. Inhibition of ERK5 signaling was shown 
to inhibit the activity of MDR1, which, in turn, increased the influx of doxorubicin into breast 
and lung cancer cells.143 Therefore, we hypothesized that MAPK inhibitors will decrease 
MDR1 and MRP1 expression to increase the efficacy of low dose chemotherapeutics. 
Surprisingly, XMD8-92 and trametinib increased MDR1 and MRP1 expression in MDA-
MB-231cells (Figure 6.6). In contrast, trametinib decreased MRP1 expression in BT-549 
cells (Figure 6.6D). Ipatasertib did not alter MDR1 or MRP1 expression in either TNBC 





Figure 6.6 XMD8-92 and trametinib modulate the expression of drug efflux 
transporters in TNBC cells. Trametinib and XMD8-92 increase (A) MDR1 and (B) MRP1 




In this study we evaluated whether low-dose chemotherapeutic drugs could 
enhance the efficacy of kinase inhibitors on cell viability in TNBC. MDA-MB-231 cells were 
less sensitive to toxic effects of doxorubicin and carboplatin compared to BT-549 cells. 
One of the reasons accounting for the difference could be the anatomical origin of the two 
models. MDA-MB-231 cells are derived from metastatic pleural effusions whereas BT-




from a metastatic site, these cells may be more aggressive and resistant to the toxic 
effects of chemotherapy.  
Trametinib was found to have an antagonistic interaction with paclitaxel and 
carboplatin in MDA-MB-231 cells. Doxorubicin, paclitaxel, and carboplatin are known 
chemotherapeutic substrates for MDR1 and/or MRP1, respectively.144 One of the possible 
mechanisms is upregulation of the drug efflux transporters MDR1 and MRP1 by 
trametinib. Since trametinib decreased MRP1 expression in BT-549 cells, this may be 
one possible mechanism for increase in sensitivity to cotreatment with doxorubicin or 
carboplatin and trametinib in BT-549 cells.  
Ipatasertib combined with the chemotherapeutic drugs was not effective at 
decreasing cell viability in TNBC cells. Ipatasertib did not alter the expression of the efflux 
transporters in either cell line. One of the reasons why cotreatment with ipatasertib with 
doxorubicin, paclitaxel, or cisplatin did not induce cell death may be that there are 
compensatory increases in alternative pathways, including the MEK5-ERK5 pathway 
following AKT inhibition by ipatasertib. In fact, dual ERK5 and AKT inhibition has been 
shown to increase paclitaxel sensitivity in TNBC.145 In  the next chapter, we examine the 
effect of dual MEK5/PI3K inhibitors on the sensitivity of chemotherapeutic drugs in TNBC.  
In conclusion, our combination data suggest that kinase inhibitors could be 
combined with chemotherapeutic drugs at low doses. Most chemotherapeutic drugs and 
kinase inhibitors are administered to the patients at the maximum tolerated dose. We 
have shown that same effect at higher doses of single drug could be recapitulated at 
lower doses of chemotherapeutic drug and kinase inhibitor. This approach could be 




Chapter 7: Evaluation of novel dual MEK5/PI3K quinazoline inhibitors in TNBC 
7.1 Introduction 
Triple negative breast cancer (TNBC) is in dire need for alternative therapies. 
Patients with TNBC expressing increased MEK5 display reduced relapse-free survival 
and increased mortality.146  MEK5 is a serine/threonine protein kinase in the three-tiered 
mitogen activated protein kinase (MAPK)  cascade that proceeds from external growth 
receptor signaling to ultimately mediate cell growth, invasion, and metastasis.  Although 
inhibiting MEK5/ERK5 would seem to be an ideal strategy for TNBC therapies, 
suppression of the MEK5/ERK5 pathway causes a compensatory increase in the activity 
of the well-known oncogene AKT.  Dual inhibition of ERK5 and AKT pathways using 
known pharmacological inhibitors has been shown to decrease cell viability and decrease 
off-target toxicity.147 Therefore, we developed novel small molecule dual ERK5/AKT 
inhibitors in collaboration with the Flaherty lab to target TNBCs. 
Our approach was to canvas the literature for known MEK5 inhibitors.  The Binding 
Database identified a compound (Figure 7.1) from the Craig Thomas lab with off-target 
MEK5 inhibition (MEK5 IC50=20 µM).  The Thomas lab forwarded a sample of the 
compound while we conducted a re-synthesis. MEK5 inhibition in our cellular inhibition of 
was identical for each compound preparation.  Subsequent analog synthesis from the 
lead compound and testing has generated over 70 compounds. These compounds were 
initially tested for MEK1,2 and 5 inhibition at a single dose of 10 µM as well as for 





Figure 7.1: Compound from Rosenthal and colleagues. 
Selected compounds from the quinazoline series identified compounds were 
inhibitors of the AKT pathway at the level of PI3K. Additionally, two of the selected 
compounds, SP-1-90 and SP-1-177 displayed both PI3K isoform selectivity and MEK5 
inhibition. The cellular IC50 values were determined for SP-1-90 and SP-1-177. 
Moreover, the lead compounds were evaluated for their effects on cell viability and 
chemotherapeutic sensitivity in MDA-MB-231 and BT-549 cells. 
7.2 Hypothesis 
Chemotherapeutic drugs will enhance the effect of dual MEK5/PI3K inhibitors on cell 
viability in triple-negative breast cancer cells. 
7.3 Results 
7.3.1 Identification of quinazolines as dual ERK5/AKT inhibitors 
 MDA-MB-231 cells (500,000 cells/well) were cultured in a 6-well plate for 24 hours. 




The quinazoline inhibitors (10 µM concentration) were added for 30 minutes prior to EGF 
(100ng/ml) stimulation for 15 minutes. Cell lysates were collected and examined for 
phospho- and total ERK5, ERK1/2, and AKT kinases using standard western blot 
procedure. Selected compounds were tested for EGFR activation to rule out off-target 
effects since the quinazoline core is conserved in several EGFR inhibitors. Substitution 
of hydrogen in K37 with a methyl group diminished EGFR activity while gaining ERK5 
selectivity (Figure 7.2). The structures and results are summarized in appendix C. 
 
Figure 7.2. Structures and kinase activity data for quinazoline series. K36 was re-
synthesis of the Rosenthal compound and used as a positive control to inhibit ERK5.  
 
7.3.2 Potency of lead compounds 
Inhibitors SP-1-190 (K33) and SP-1-182 (K46) were selected based on their kinase 








Figure 7.3 SP-1-177 and SP-1-182 are potent dual MEK5/PI3K inhibitors. 
7.3.3 Doxorubicin enhances sensitivity of SP-1-177 in MDA-MB-231 cells 
 The lead compounds from diphenylamine (SC-1-181), thiophene (MG-5-5), and 
quinazoline (SP-1-77 and SP-1-182) series were combined with low-dose 
chemotherapeutic drugs paclitaxel, doxorubicin, and carboplatin to examine synergy in 
MDA-MB-231 and BT-549 cells. We found that SP-1-177, a dual MEK5/AKT inhibitor 




alone significantly decreased cell viability in BT-549 cells, there was no further reduction 
in cell viability observed in combination with chemotherapeutic drugs. SC-1-181 and SP-
1-90 enhanced doxorubicin sensitivity in BT-549 cells.  
 
 
Figure 7.4: Effect of novel MAPK inhibitors in combination with chemotherapeutic 
agents on cell viability. (A) MDA-MB-231 and (B) BT-549 cells were treated with 1μM 
novel inhibitor in the presence of DMSO or low-dose paclitaxel, doxorubicin, and 
carboplatin for 72 hours. MTT assay was performed to assess cell viability. Data 






























the Bonferroni post hoc test. *p<0.05; **P<0.01; ***P<0.001; ****P<0.0001 vs DMSO; 
#P<0.05, ##P<0.01; ####P<0.0001; vs individual drug determined by one-way ANOVA 
with the Bonferroni post hoc test. 
 
7.4 Discussion 
Due to crosstalk between the ERK5 and AKT pathways, it is important to develop 
dual targeting agents to simultaneously target both the pathways. In the current chapter, 
through structure-activity relationships studies, novel MEK5/PI3K inhibitors were 
identified and characterized for their selective activity against ERK5 and AKT, the 
downstream substrates of MEK5 and PI3K, respectively. In the previous chapter, we 
observed synergy with single agent kinase inhibitors in combination with 
chemotherapeutic drugs. Addition of a pan-PI3K inhibitor GD-0941 to docetaxel showed 
synergy in mouse xenograft models.148 Clinically, BMK120, a pan-PI3K inhibitor and 
paclitaxel combination reversed paclitaxel drug resistance in patients with advanced solid 
tumors.149 Paclitaxel was found to enhance cytotoxicity by ipatasertib and XMD8-92 
combination in MDA-MB-231 cells.145 The effect of chemotherapeutic drugs on cytotoxic 
effects of dual MEK5 and PI3K inhibitors in TNBC is currently unknown. In this study, we 
combined the chemotherapeutic drugs with lead MEK5 inhibitors or dual PI3K inhibitors 
from the diphenylamine,83 thiophene,150 and quinazolines at low doses and examined 
their effect of on cell viability.  
While doxorubicin did not sensitize the effect of MEK5 inhibitor SC-1-181 on cell 
viability, doxorubicin significantly enhanced the sensitivity of MDA-MB-231 cells to a dual 
MEK5/PI3K inhibitor SP-1-177. SP-1-177 produced a greater reduction in cell viability 




chemotherapeutic drugs in BT-549 cells. In this study, the chemotherapeutic drugs and 
kinase inhibitors were added simultaneously. Sequence of drug administration could alter 
cellular response.151 Future studies focus on examining the effect of sequential addition 

















Chapter 8: Dual inhibition of MEK5 and MEK1/2 or PI3K pathways decreases cell 
viability, proliferation, migration, and stemness, and induces mesenchymal to 
epithelial transition in glioblastoma multiforme 
8.1 Introduction 
 Glioblastoma multiforme (GBM) is a very aggressive form of cancer with median 
survival of only 14-15 months despite standard therapy consisting of surgery, adjuvant 
radiation, and chemotherapy. Infiltration into surrounding tissue decreases the success 
of surgical removal of the tumor and further increases the rate of recurrence.152-153 
Hyperactivation of PI3K and MAPK pathways is a frequent event in most GBM cases. 
Moreover, the mesenchymal subtype of GBM is driven by activation of the ERK1/2 






Figure 8.1: ERK pathway in GBM.154 
The goals of the current research are to identify therapeutic targets and 
interventions for the treatment of glioblastoma multiforme, which has the worst prognosis 
and decreased overall survival compared to other brain cancers. There are no current 
therapies that are effective to treat patients with GBM. There is an urgent need to identify 
relevant targets that can be inhibited therapeutically to improve prognosis of GBM 
patients. MAPK and PI3K pathways are recently identified to promote GBM 
progression.155 We first utilized a bioinformatics approach to compare genes downstream 
of MAPK and PI3K pathways and those involved EMT and proliferation in healthy versus 
GBM tumor samples using publicly available datasets. The MAPK7 gene codes for the 
newest member of the MAPK pathway, extracellular signal-regulated kinase ERK5, and 
is significantly upregulated in GBM tumor samples compared to healthy control. GBM 
tumor samples were enriched in EMT markers and genes involved in cell proliferation, 
which are known downstream targets of MAPK and PI3K pathways.  
Activation of AKT is an important event in GBM progression due to mutation in 
PTEN or PI3K. One of the limitations of PI3K pathway inhibitors is compensatory 
increases in alternative pathways, including the MEK5-ERK5 pathway.145 This 
necessitates the development of novel and relevant combination strategies to target 
GBM. We have previously shown that dual inhibition of AKT and ERK5 or triple inhibition 
of AKT, ERK5, and BRD4 is a relevant strategy to target triple-negative breast cancer 
(TNBC).145 Moreover, the crosstalk between ERK5 and AKT pathways has been 
previously noted in neuroblastomas.39 Therefore, we evaluated the effect of dual inhibition 




a major oncogenic driver in GBM, which was found to be upregulated and positively 
correlated with MAPK7 in GBM patient samples. Bromodomain inhibitors were developed 
with a rationale to target the MYC oncogene in cancer.156 Therefore, a dual MEK5/PI3K 
inhibitor J19 (MG-3-81)150 was used alone and in combination with CPI-203, a BRD4 
inhibitor. We also examined the effects of previously reported novel inhibitors of MEK5 or 
MEK1/2 pathways, which reversed the mesenchymal phenotype of TNBC157 on EMT in 
GBM.  
8.2 Hypothesis 
Dual inhibition of the MEK5 and MEK1/2 or PI3K pathways will induce MET and decrease 
cell viability, proliferation, migration, and colony formation in PTEN mutant GBM cells with 
a mesenchymal phenotype. 
8.3 Results 
8.3.1 MAPK7 gene expression is significantly upregulated in GBM tumor samples 
compared to healthy groups  
Glioblastoma multiforme (GBM) was identified to have the worst prognosis among 
other forms of cancers that originate in the brain (Figure 8.2A). MAPK7 gene, which codes 
for protein ERK5 was found to be significantly upregulated in GBM tumor samples 
compared to healthy group (Figure 8.2B). In contrast, MAPK1 and MAPK3 genes were 
significantly downregulated in GBM vs. healthy group. Epithelial cell markers CDH1 and 
keratin 1 (KRT1) were significantly downregulated, whereas tight junction protein (TJP1) 
gene expression did not decrease in GBM versus healthy group. Mesenchymal cell 




expected, genes involved in cell proliferation KI67, CCND1, and PCNA were significantly 
upregulated in GBM versus healthy group. Upstream regulator of MAPK pathway, EGFR 
was significantly upregulated while there was no increase in PIK3CA gene; however, 
there was a significant decrease in PTEN gene, which inhibits AKT activation by 
dephosphorylation. There was a significant increase in AKT1 and AKT2 and decrease in 
AKT3 gene expression (Figure 8.2B).   
8.3.2 MAPK7 gene expression positively correlates with the EMT markers in GBM 
tumors 
ERK5 is known to antagonize the decrease in MYC induced by KRAS suppression, 
indicating that ERK5 may be upstream of MYC.53 Interestingly, there was a significant 
positive correlation between MAPK7 and MYC in GBM. To understand whether ERK5 
regulates genes involved in EMT and stemness, MAPK7 gene expression was correlated 
to stem cell markers PROM1 (gene that codes for CD133), NOTCH1, epithelial cell 
marker CDH1 (gene that codes for E-cadherin), and mesenchymal markers VIM and 
ZEB1. MAPK7 gene expression negatively correlated with CDH1 (Figure 8.2D) and 
positively correlated with stemness markers PROM1 and NOTCH1 (Figure 8.2E, H) and 
mesenchymal markers VIM and ZEB1 (Figure 8.2F, G), suggesting a role for ERK5 in 













Figure 8.2. Comparison of genes downstream of MAPK and PI3K pathways in 
tumors derived from GBM patients versus healthy groups. (A) Kaplan-Meier survival 
analysis in different subtypes of brain cancer (B) Gene expression analyses in healthy 
tissues versus GBM patient samples. Gene correlation between MAPK7 and (C) PROM1 
(D) CDH1, (E) MYC (F) VIM, (G) ZEB1, or (H) NOTCH1. Data were plotted using R2: 
Genomics analysis and visualization platform (https://hgserver1.amc.nl/cgi-
bin/r2/main.cgi). Datasets were exported from Tumor Brain (REMBRANDT study) - 
Madhavan - 550 - MAS5.0 - u133p2. 
 
8.3.3 MAPK1, MAPK7, AKT1, and AKT2 gene expression is associated with poor 
patient survival in GBM 
 Kaplan Meier survival analysis was performed to examine the association of MAPK 
and PI3K pathways on overall survival in GBM using publicly available datasets. High 
MAPK1 (gene that codes for ERK2), MAPK7 (gene that codes for ERK5), AKT1 and AKT2 
expression was associated with worse patient outcome whereas high MAPK3 (gene that 
codes for ERK1) and AKT3 expression was associated with better patient outcome 






Figure 8.3. MAPK3, MAPK1, and MAPK7 expression correlates with poor patient 
survival in GBM. Disease free survival was analyzed using R2: Genomics analysis and 
visualization platform (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi). Datasets were 
exported from Tumor Brain (REMBRANDT study) - Madhavan - 550 - MAS5.0 - u133p2. 
 
8.3.4 Dual inhibition of ERK5 and AKT pathways synergistically reduces cell 
viability in GBM 
 U87MG cells are PTEN mutant and may rely on the AKT pathway for survival and 
proliferation. Since crosstalk between AKT and ERK5 may exist, the effects of ipatasertib, 
an AKT inhibitor and XMD8-92, an ERK5 inhibitor alone and in combination were 
examined on kinase activation, cell viability, and migration. To determine the specificity 
of kinase inhibitors, U87MG cells were serum starved for 18 hours after 24 hours of cell 




for 15 minutes. Cell lysates were collected and examined for ERK1/2, ERK5, and AKT 
activation. As expected, XMD8-92 and XMD8-92+ipatasertib groups decreased ERK5 
activation with no effect on AKT or ERK1/2 activation. Ipatasertib targets the ATP-site 
and keeps AKT in its active form and decreases downstream signaling by AKT. This may 
explain while there was no decrease in AKT activation, there was still a decrease in cell 
viability after treatment with ipatasertib. Ipatasertib modestly increased ERK5 activation 
(Figure 8.4A). Neither of the inhibitors altered ERK1/2 activity. Targeting AKT alone led 
to compensatory increase in ERK5 activation, which was inhibited in the Ipat+XMD8-92 
group compared to control (Figure 8.4A).  
While both ipatasertib and XMD8-92 were effective at decreasing cell viability in a 
concentration-dependent manner (Figure 8.4B-C), combination of ipatasertib with XMD8-
92 produced a greater reduction in cell viability. 1:3 combination of ipatasertib and XMD8-
92 was more effective than 1:1 ratio at increasing the fraction affected as calculated by 
using CompuSyn software (Figure 8.4D). While ipat or XMD8-92 did not decrease cell 





Figure 8.4. Dual ERK5 and AKT decreases cell viability and migration in U87MG 
GBM cells. (A) Western blot analysis of ERK5, ERK1/2, and AKT activation by EGF in 
U87MG cells (B) Cells were treated with XMD8-92 and ipatasertib at increasing 
concentrations for 72 hours. Data represent the ± SEM of three different experiments for 
each inhibitor compared to DMSO control. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 
vs DMSO control group determined by one-way ANOVA with the Bonferroni post hoc test. 
(C) Combination index table for synergy determination. (D) Effect of ipatasertib and 
XMD8-92 at 1 and 3 μM concentration, respectively on cell migration in U87MG cells. 
Scratches were made after 24 hours of cell seeding (0h) and cells were treated with the 
kinase inhibitors for 24 hours. Cells were imaged at the time of scratch (0 h) and after 24 
hours from the time of scratch (20X magnification). (Synergy data: Dr. Thomas Wright) 
 
Ipat+XMD combination did not significantly decrease the proliferative fraction (Figure 8.5), 





Figure 8.5: Ipat+XMD combination does not decrease proliferative fraction in 
U87MG cells. (Katie Anna). Cells were treated with indicated inhibitors for 72 hours (20X 
magnification). Proliferative fraction was evaluated as the number of Ki67 positive cells 
divided by the number of Hoechst positive cells. Data represent the ± SEM of three 
different experiments. *p<0.05; **p<0.01; ***p<0.001 vs. DMSO control group determined 
by one-way ANOVA with the Bonferroni post hoc test. 
 
8.3.5 Dual PI3K/MEK5 inhibitor+CPI203 combination significantly decrease cell 
proliferation via p21 restoration in GBM 
BRD4 regulates cell cycle progression via upregulation of c-Myc and cyclinD1, 
which are also downstream targets of MAPK pathways. Several dual PI3K/MEK5 
thiophene analogs were developed as novel therapeutic interventions to target cancer. In 
this study, we examined the effect of novel dual MEK5/PI3K inhibitor J19 (MG-3-81) in 
combination with BRD4 inhibitor CPI-203 on cell proliferation. Ipatasertib, J19 (MG-3-81), 
or CPI-203 alone did not significantly decrease the proliferative fraction as determined by 
taking the ratio of Ki67+ cells to Hoechst+ cells. While ipatasertib did not potentiate the 
effect of CPI203 on cell proliferation, J19 (MG-3-81)+CPI-203 combination significantly 
decreased proliferative fraction to a greater extent compared to either drug alone (Figure 
8.6A). The decrease in cell proliferation correlated with an increase in p21, a cell cycle 






Figure 8.6. Effect of ipatasertib and J19 (MG-3-81) alone and in combination with 
CPI-203 on cell proliferation and p21 expression in U87MG cells. (A) Cells were 
treated with indicated inhibitors for 72 hours (20X magnification). Proliferative fraction was 
evaluated as the number of Ki67 positive cells divided by the number of Hoechst positive 




***p<0.001 vs. DMSO control group determined by one-way ANOVA with the Bonferroni 
post hoc test. (Seraina Schottland). 
 
8.3.6 Dual MEK1/2 and MEK5 inhibitor(s) and LBH589 (HDAC inhibitor) induce MET 
in U87MG glioblastoma cells. 
Reversing EMT is an emerging approach to target cancer. We have previously 
shown that pharmacological inhibitors of MEK1/2 and MEK5 pathways reversed EMT in 
triple-negative breast cancer.157 U87MG cells were treated with novel MEK1/2 inhibitor 
(SC-1-122), MEK5 inhibitor (SC-1-181), dual MEK1/2 and MEK5 inhibitor (SC-1-151), 
LBH589, trametinib, or XMD8-92 for 72 hours. The phenotypic switch from mesenchymal 
to epithelial was most prominent in SC-1-151, trametinib, and LBH-589-treated groups 
(Figure 8.7A-B). We hypothesized that targeting the AKT pathway may be a relevant 
strategy to reverse EMT; however, ipatasertib, J19 (MG3-81), or CPI-203 did not reverse 
EMT in these cells (Figure 8.7A). Therefore, the ERK1/2 and ERK5 pathways may play 






Figure 8.7: Effect of novel and known MAPK inhibitors on MET in U87MG cells. (A) 
U87MG cells were treated with MAPK inhibitors for 72 hours and stained with crystal violet 
after 72 hours of treatment. (B) Cell morphology was quantified by morphometric analysis 
10X (Jordan Martin). 
 
8.3.7 Trametinib decreases ERK5 activation, cell viability, migration, and colony 
formation in GBM 
Since trametinib was most effective at reversing EMT, we further characterized its 
effects on kinase activation by EGF to determine its specificity, and cell viability, 
migration, and colony formation assays. U87MG cells were serum starved for 18 hrs and 
treated with trametinib at 0.1 and 1 μM concentrations for 30 minutes. Cells were then 
stimulated with EGF for 15 minutes. Lysates were collected and examined for ERK5, 
ERK1/2, and AKT activation. As expected, trametinib decreased ERK1/2 activation by 
EGF. Surprisingly, trametinib also inhibited ERK5 activation by EGF (Figure 8.8A). MTT, 
migration, and colony formation assays were performed to examine the effects of 




viability at 10 μM concentration (Figure 8.8B) and significantly inhibited cell migration and 
colony formation, consistent with its effect on MET in U87MG cells (Figure 8.8C-D). 
 
 
Figure 8.8. Trametinib decreases ERK5 activation, cell viability, migration, and 
colony formation in U87MG cells. (A) ERK5 and ERK1/2 activation (B) cell viability (C) 
migration (D) colony formation and CD133 expression in U87MG GBM cells. **p<0.01 vs 
control group determined by Student’s t-test.   
8.4 Discussion  
  Glioblastoma multiforme is an aggressive disease with limited therapeutic options. 
ERK1/2, ERK5, and AKT pathways are important targets in glioblastoma. However, the 
crosstalk between ERK5 and AKT and effects of MAPK inhibitors on proliferation, EMT, 
and stemness in glioblastoma are not well-understood. Therefore, we examined the effect 
of novel and known MAPK pathway inhibitors in combination with PI3K pathway 




Recent studies suggest that ERK5 expression and activation are crucial events in 
regulating EMT in several cancers90, 105 and targeting the MAPK pathways has been 
shown to reverse EMT in breast cancer.157-158 One goal of this research was to identify 
pathways that were significantly upregulated in GBM compared to healthy controls, so as 
to  therapeutically target the aberrant pathways. Recent evidence suggests that EGFR, 
PI3K, and PTEN mutations159 are common oncogenic drivers in GBM, making GBM a 
relevant disease model to study ERK1/2, ERK5, and AKT protein kinases as relevant 
drug targets in GBM. From our research, using publicly available datasets from Gusev et 
al.,160 we examined specific components of MAPK and PI3K pathways, which were 
upregulated in GBM versus healthy control.  
MAPK7 was found to be significantly upregulated in GBM versus healthy control. 
Therefore, we correlated MAPK7 gene expression to EMT and proliferation markers. 
There was a significant increase in the upstream regulator of MAPK pathways, epidermal 
growth factor receptor (EGFR), in agreement with previous reports.161  
PTEN deletion is a common event in GBM.159 Since PTEN expression was 
significantly downregulated in GBM versus healthy control, AKT may be a relevant target 
in GBM. Moreover, high AKT1 and AKT2 expression was associated with worse patient 
outcome. Since high MAPK3 and AKT3 gene expression correlated with better patient 
outcome, it may be important to develop isoform-specific pharmacological inhibitors of 
ERK1, AKT1, or AKT2, which spare ERK2 or AKT3 activity. Isoform-specificity of 
inhibitors are currently being investigated in our laboratory and others.162 Data suggest it 





While we obtained information about putative drug targets by utilizing a 
bioinformatics approach, these observations do not provide insights into whether there is 
a subsequent increase in protein expression or activation in different components of the 
MAPK and PI3K pathways. Therefore, we utilized an in vitro approach to inhibit these 
pathways using known and novel inhibitors of the MAPK and PI3K pathways to examine 
their effect on kinase activation, proliferation, EMT, and stemness.  To understand 
whether targeting ERK5, ERK1/2, and/or PI3K pathways was promising in GBM, we 
utilized PTEN-mutant U87MG cells with moderate EGFR expression and a mesenchymal 
phenotype.163-164 In addition to genes involved in the regulation of proteins that promote 
EMT, cell proliferation genes downstream of MAPK, AKT, and bromodomain pathways 
were significantly enriched in GBM tumors compared to healthy control. Compensatory 
activation of the AKT or BET proteins may reactivate MAPK-mediated proliferation in 
cancer cells.129 Therefore, combination strategies were designed to target both MAPK 
and bromodomain proteins in U87MG cells. Similar to our findings in breast cancer, dual 
ERK5 and AKT inhibition significantly decreased cell viability and migration in U87MG 
cells. Novel dual PI3K/MEK5 inhibitor J19 (MG-3-81) was more effective in combination 
with BRD4 inhibitor CPI-203 to decrease cell proliferation compared to AKT inhibitor 
ipatasertib. Our data suggest that this decrease in cell proliferation was mediated at least 
in part via p21 restoration.  
U87MG cells were especially susceptible to dual targeting of ERK1/2 and ERK5 
pathways since treatment with dual MEK1/2 and MEK5 inhibitor significantly decreased 
the percentage of cells with SI>3 when compared with DMSO control or inhibition 




expression significantly correlated with mesenchymal markers ZEB1, vimentin, and 
inversely correlated with epithelial marker E-cadherin, MEK5 inhibitor SC-1-181 did not 
reverse EMT in U87MG cells. This may be because ERK1/2 pathway is still active. 
Trametinib, a MEK1/2 inhibitor reversed EMT in U87MG cells. To our knowledge, this is 
the first study to show the effect of MEK1/2 inhibition on reversal of EMT in glioblastoma. 
A previous study has reported that downregulation of ERK5 by microRNA-200 
suppressed EMT in GBM.44 This may indicate that total ERK5 expression, rather than its 
activation may be a driver of EMT in GBM. Trametinib decreased total ERK5 expression 
even at short time points (Figure 8.8A), which may indicate that inhibition and decrease 
in total ERK5 expression may be necessary for full effect of trametinib on MET in U87MG 
cells. LBH589, a histone deacetylase inhibitor was used as a positive control since it 
known to reverse EMT in some cancers.165 The possible reasons why ERK5 inhibition 
alone did not reverse EMT may be because total ERK5 expression may regulate 
transcription of genes in the nucleus even in the absence of phosphorylated ERK5 in the 
cytosol.166  
MEK1/2 inhibitor trametinib decreased ERK1/2 and ERK5 activation in response 
to EGF. ERK1/2 and ERK5 pathways share ~50% sequence homology at the N-terminal 
domain.167 Trametinib-mediated decrease in ERK5 activation may be mediated via 
MEK1/2 inhibition. Trametinib decreased viability, migration, and colony formation in 
U87MG cells, indicating that dual MEK1/2 and MEK5 inhibition is a relevant strategy to 
target EMT in GBM. Overall, our data suggest that ERK1/2 and ERK5 are relevant targets 
to reverse the EMT and ERK5 and AKT are relevant targets to decrease cell viability and 




conclusion, this is the first study to examine the effects of pharmacological inhibition of 
MEK5 and MEK1/2 or PI3K pathways on cell proliferation, migration, stemness, and EMT 
in GBM.  
 
 
Figure 8.9: Regulation of cell viability, EMT, and stemness via the MAPK and PI3K 










Chapter 9: Marine cyanobacteria inhibit cell viability and enhance 
chemotherapeutic sensitivity in triple-negative breast cancer 
9.1 Introduction 
 TNBCs are in dire need for alternative therapies. There is also an urgent need to 
identify novel targets to develop treatment options, which can selectively target cancer 
cells. A recent review of the literature168 has identified a number of marine cyanobacterial 
peptide and peptide-containing natural  compounds that display antitumor cytotoxicity. 
Sigma-2 receptors was identified as transmembrane protein 97.169 In this chapter, we will 
discuss the effects of novel marine peptides, veraguamide M and N, that are putative 
ligands for sigma-2 receptors, which are overexpressed in TNBCs and promote 
tumorigenesis. Moreover, sigma 2 receptor ligands have been shown to be toxic in 
neuroblastoma, and mouse breast cancer cell lines.170-171 Sigma 2 receptor selective 
compounds have also been reported to decrease MCF-7 and doxorubicin-resistance 
MCF7 breast cancer cell proliferation and enhance the sensitivity of MCF-7 cells to 
doxorubicin21,22. Currently, there is only one study that examines the synergistic effects 
of sigma 2 receptor ligands with PARP inhibitors in MDA-MB-231 TNBC cells and one 
other study that examines synergy with taxol and a cytotoxic payload delivered to TNBC 
cells via conjugation to a sigma 2 receptor ligand23. In this study, we examined the 
expression of TMEM97, a gene that codes for sigma 2 receptors, in breast cancer 
subtypes. Next, we examined the effect of novel sigma 2 ligands on cell viability and 






Chemotherapeutic drugs will enhance cytotoxic effects of novel sigma 2 receptor ligands 
in triple-negative breast cancer cells. 
9.3 Results 
9.3.1 High expression of TMEM97 in diverse breast cancer subtypes is associated 
with poor overall survival 
 Bioinformatic analyses of publicly available datasets from Bertucci and 
colleagues109 was performed to determine the expression of TMEM97 in diverse breast 
cancer subtypes. TMEM97 expression was higher in luminal a, luminal b, erbb2, and 
basal like cancers compared to normal (Figure 9.1A). Higher expression of TMEM97 also 
decreased disease free survival as compared to breast cancer patients with low tumore 





Figure 9.1: TMEM97 is overexpressed in cancer versus healthy groups and high 
TMEM97 expression correlates with poor overall survival in breast cancer patients. 
(A) TMEM97 is overexpressed in cancer versus healthy control (B) High TMEM97 
expression correlates with poor patient survival in breast cancer. Disease free survival 
was analyzed using R2: Genomics analysis and visualization platform 
(https://hgserver1.amc.nl/cgi-bin/r2/main.cgi). Datasets were exported from Tumor 
Breast (MDC) Bertucci - 266 - MAS5.0 - u133p2. 
 
9.3.2 Marine cyanobacteria inhibit viability in MDA-MB-231 cells 
 MDA-MB-231 cells were treated with marine cyanobacteria fractions at 0.1, 1, and 
10 ug/ml concentrations for 72 hours. MTT assay was performed to determine cell 
viability. Fractions B, C, D, E, and F significantly decreased cell viability (Figure 9.2). 
Barbamide was extracted from fraction F to determine its effect on cell viability. 
Barbamide produced a significant decrease in cell viability in MDA-MB-231 and BT-549 







Figure 9.2: Barbamide produced a concentration-dependent decrease in cell viability in 
MDA-MB-231 cells after 72 hours of treatment. Data represent the ± SEM of three different 
experiments. *p<0.05; **p<0.01; ****p<0.0001 vs control group determined by one-way ANOVA 
with the Bonferroni post hoc test. 
 
9.3.3 Effect of marine cyanobacteria in combination with chemotherapy on TNBC 
cell viability  
 Sigma 2 receptor ligands have been shown to synergize with doxorubicin to inhibit cell 
growth in MCF-7 cells.172 However, studies of synergy of sigma 2 ligands with 
doxorubicin, paclitaxel, and cisplatin in TNBC have not been done. Therefore, we 
combined two natural sigma 2 receptor ligands veraguamide and barbamide with 
chemotherapeutics, doxorubicin, paclitaxel, and carboplatin at low doses. The toxic effect 
of veraguamide was enhanced by doxorubicin and carboplatin in MDA-MB-231 and BT-
549 cells. The toxic effects of barbamide was enhanced by doxorubicin and carboplatin 






Figure 9.3: Effect of (A) veraguamide and (B) barbamide on chemotherapeutic 
sensitivity in MDA-MB-231 cells. Data represent the ± SEM of three different 
experiments. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 vs control group #p<0.05; 
###p<0.001; ####p<0.0001 vs chemotherapeutic drug alone determined by one-way 






Figure 9.4: Effect of (A) veraguamide and (B) barbamide on chemotherapeutic 
sensitivity in BT-549 cells. Data represent the ± SEM of three different experiments. 
*p<0.05; **p<0.01; ***p<0.001 vs control group #p<0.05; ##p<0.01; ###p<0.001; 
####p<0.0001 vs chemotherapeutic drug alone determined by one-way ANOVA with the 
Bonferroni post hoc test. 
 
9.4 Discussion 
 Novel cyanobacterial compounds have been identified as sigma 2 receptor ligands. 
From the initial screen of cyanobacterial fractions, barbamide was isolated from fraction 
F. Veraguamide and barbamide were used at low doses in combination with 
chemotherapeutic drugs. There was a modest increase in cytotoxicity of veraguamide 




barbamide will be synthesized as putative sigma 2 receptor ligands as alternative 
therapies for diverse breast cancer subtypes.  Since natural compounds may be well-
tolerated, future studies will examine the effect of low-dose chemotherapeutic drug in 




















Chapter 10: Conclusion and future directions 
Cancer metastasis accounts for 90% cancer related deaths. EMT is the first step 
in cancer metastases cascade and there are no therapeutic agents, which are known to 
reverse EMT in aggressive cancer cells with a mesenchymal phenotype. ERK1/2 and 
ERK5 pathways are known to induce EMT in several cancers; however, the effect of 
inhibition of the ERK1/2 and ERK5 pathways on the reverse of EMT is not well-understood 
in cancer. In our research, we utilized bioinformatics, drug discovery, and in vitro 
approaches to develop strategies to reverse EMT and attenuate tumor forming and 
metastatic abilities of breast and brain cancers.  
Epigenetic pathways and crosstalk with the PI3K pathway may lower the efficacy 
of ERK1/2 or ERK5 inhibitors on cell viability. Therefore, we designed combination 
strategies to simultaneously target MAPK and PI3K pathways to target cell viability in 
triple-negative breast cancer. Development of chemotherapeutic drug resistance is 
another major problem associated with cancer. Emerging evidence suggests a role of 
MAPK pathway in mediating chemo-resistance in cancer. Therefore, we developed 
rational combination strategies to treat cancer cells with a combination of low-dose kinase 
inhibitors and chemotherapeutic drugs and examined their effect on cell viability. The idea 
is to utilize low doses of drugs in combination to achieve the same effect as high doses 
of drugs alone to prevent collateral toxicity. In future, it would be worth assessing whether 
treating cells with low-dose kinase inhibitors would prevent chemoresistance or treatment 
of cells that have developed resistance to chemotherapeutic drugs with kinase inhibitors 




In conclusion, we have reported for the first time the effect MAPK pathway 
inhibition on mesenchymal to epithelial transition, the reverse of EMT, nuclear localization 
of ERK5 and ERK1/2, and crosstalk with the PI3K-AKT pathway in regulation of EMT and 
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Appendix B Antibody inventory 












92668021 C50618-03 G R IRDye 680LT WB ICW 
92632210 C30701-01 G M IRDye 800CW WB ICW 
A21429 1371057 G R Alexa Fluor 555 IF F IHC 














ERK5 R 115 3372 WB IP 
pERK5 
(Thr218/Tyr20) 
R 115 3371 WB 
ERK1/2 (p44/42) M 44, 42 4695 WB IP IHC  
pERK1/2 (phospho-
p44/42) 
R 44, 42 9101 WB IP IF F 
AKT (Ser 173) R 60 9272 WB IP IHC 







E-Cadherin R 135 3195 WB IHC IF F 
N-Cadherin R 140 13116 WB IP IHC IF 
Vimentin R 57 5741 WB IHC IF F 
ZO-1 R 220 5406 WB IP 
Snail R 29 3879 WB IP 
Slug R 30 9585 WB IP 
TCF8/ZEB1 R 200 3396 WB IP 






R 32  WB IHC IF F 
Ki67 (cell proliferation 
marker) 
R   IHC 
SOX2 (stem cell 
biomarker) 
R 39 AB5603 WB IHC IF 
Loading 
control 
α-tubulin M 52 3873 WB IHC IF 
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Appendix D KEGG analysis of pathways upregulated in glioblastoma multiforme 
Goal: To identify pathways that are upregulated in GBM. 
Method: KEGG pathway analysis was performed to examine the pathways that are 
upregulated in GBM tumor samples compared to non-tumor controls.  
Result: MAPK signaling pathway and genes involved in regulation of the actin 
cytoskeleton were among the top fifteen categories of significantly upregulated genes. 
These findings suggest that MAPK pathway is an important target in GBM. The 
signaling is also outlined below.  
Tumor Brain (REMBRANDT study) - Madhavan - 550 - MAS5.0 - u133p2 public  
disease~glioblastoma_multiforme,normal 256 of 550 samples, transform_log2 
Grouping variable: disease 
present calls >=1, selected genes (6968) 
3298 combinations meet your criteria 
2114 combinations did not meet T-test p<0.0001 as R and 1 as minimal # of 
PresentCalls 
Date of data procurement: 2-14-2021 
Links Group In_Set Total Percentage p-value 
- All 3298 5412 60.9% - 
R K A Axon_guidance 98 121 81.0% 6.1e-06 
R K A Retrograde_endocannabinoid_signaling 74 89 83.1% 1.8e-05 
R K A Spliceosome 91 119 76.5% 5.2e-04 
R K A Glutamatergic_synapse 82 106 77.4% 5.3e-04 
R K A Nicotine_addiction 29 32 90.6% 5.8e-04 
R K A GABAergic_synapse 61 77 79.2% 1.0e-03 
R K A Synaptic_vesicle_cycle 47 58 81.0% 1.7e-03 
R K A Long_term_potentiation 49 61 80.3% 1.9e-03 
R K A MAPK_signaling_pathway 161 227 70.9% 2.0e-03 
R K A Circadian_entrainment 63 83 75.9% 5.2e-03 
R K A Serotonergic_synapse 67 89 75.3% 5.5e-03 
R K A Regulation_of_actin_cytoskeleton 133 189 70.4% 7.9e-03 
R K A Pancreatic_cancer 50 65 76.9% 8.3e-03 
R K A Lysosome 81 111 73.0% 9.4e-03 
R K A N_Glycan_biosynthesis 37 47 78.7% 0.01 
R K A Amphetamine_addiction 46 60 76.7% 0.01 




R K A Endometrial_cancer 39 51 76.5% 0.02 
R K A Oxytocin_signaling_pathway 97 138 70.3% 0.02 
R K A MicroRNAs_in_cancer 104 149 69.8% 0.03 
R K A Morphine_addiction 59 81 72.8% 0.03 
R K A Progesterone_mediated_oocyte_maturation 59 81 72.8% 0.03 
R K A Shigellosis 44 59 74.6% 0.03 
R K A Ribosome 76 107 71.0% 0.03 
R K A Vibrio_cholerae_infection 33 43 76.7% 0.03 
R K A DNA_replication 28 36 77.8% 0.04 
R K A ErbB_signaling_pathway 61 85 71.8% 0.04 
R K A Glycosaminoglycan_degradation 13 15 86.7% 0.04 
R K A Arginine_and_proline_metabolism 32 42 76.2% 0.04 
R K A Platelet_activation 76 108 70.4% 0.04 
R K A Mismatch_repair 18 22 81.8% 0.04 
R K A Lysine_degradation 36 48 75.0% 0.05 
R K A Cholinergic_synapse 70 99 70.7% 0.05 
R K A Focal_adhesion 129 190 67.9% 0.05 
R K A Dopaminergic_synapse 81 116 69.8% 0.05 
R K A Protein_processing_in_endoplasmic_reticulum 105 153 68.6% 0.05 
R K A Bladder_cancer 29 38 76.3% 0.05 
R K A Wnt_signaling_pathway 86 124 69.4% 0.05 
      
 



























Appendix E: Supporting Figures 
 
Hypothesis: Novel diphenylamine compounds will induce MET in TAMR MCF-7 cells. 
Method: TAMR MCF-7 cells were treated with diphenylamine compounds for 5 days. 
The cells were fixed and stained with crystal violet dye and pictures were taken using 
EVOS.  
Result: Compounds reverse EMT in TAMR MCF-7 cells. The SAR obtained in MDA-
MB-231 cells was consistent across another model of breast cancer with a 
mesenchymal phenotype. 
 
Consistent with MDA-MB-231 cells, treatment with compounds 1, 2, and 9 induced 
an MET in TAMR MCF-7 cells as examined by crystal violet staining of cells after 




Goal: To examine the effect of diphenylamine analogs on AKT activation in MDA-MB-
231 cells. 
Method: MDA-MB-231 cells were treated with diphenylamine compounds for 5 days. 
Cell lysates were collected and examined for ERK1/2 and AKT activation via western 
blotting.  
Result: Compounds that inhibited ERK1/2 activation produced a compensatory 




Novel diphenylamine analogs and MEK1/2 or MEK5 inhibitors that inhibit MEK1/2 





Hypothesis: Dual inhibition of ERK1/2 and ERK5 pathways will induce a MET in MDA-
MB-231 cells. 
Method: MDA-MB-231 cells were treated with MEK1/2 inhibitor UO126 and ERK5 
inhibitor AX15836 alone and in combination for 5 days. The cells were fixed and stained 
with crystal violet dye and pictures were taken using EVOS. Cell lysates were collected 
to examine E-cadherin protein expression. To determine kinase activation, MDA-MB-
231 cells were serum starved after 24 hours of plating. Inhibitors were added for 30 
minutes followed by 15 minutes of EGF stimulation. 
Result: UO126 alone and in combination with AX15826 induces a mesenchymal to 
epithelial transition in MDA-MB-231 cells as determined by cell morphology and 
increase in E-cadherin expression. Moreover, treatment with UO126 and AX15836 
significantly decreased ERK5 activation by EGF. ERK5 inhibitor AX15836 also inhibited 





Compound 1 (SC-1-151) – like effects on cell morphology and E-cadherin protein 
expression could be recapitulated by addition of combination of ERK1/2 inhibitor 
UO-126 and ERK5 inhibitor AX15836. 
 
UO+AX combination significantly decreased ERK5 activation by EGF.  Moreover, 
AX15836 significantly decreased ERK1/2 activation by EGF.  
 
Hypothesis: Sequential addition of chemotherapeutic drugs after cells undergo MET 
will be beneficial to enhance chemosensitivity in TNBC cells. 
Method: MDA-MB-231 and BT-549 cells were treated with trametinib, XMD8-92, or 
combination of Tra+XMD for 48 hours followed by chemotherapeutic drugs for 24 hours. 




Result: Our data indicate that prior treatment with kinase inhibitors does not sensitize 
the cells (which are in the process of undergoing MET at this stage) to 
chemotherapeutic drugs paclitaxel, doxorubicin, or carboplatin. Control (Con.) , [Tra] low 
= 0.01, mid= 0.1, high=1 uM; [XMD] low = 0.1, mid= 1, high= 10 uM; [Tra], [XMD]: low = 
0.01, 0.1), Med= 0.1, 1, High= 1, 10. This may be because of increase in drug efflux 
transporters after treatment with kinase inhibitors. 
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